DEF 14A 1 cvs3324661-def14a.htm DEFINITIVE PROXY STATEMENT

Table of Contents

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 14A

Proxy Statement Pursuant to Section 14(a) of the
Securities Exchange Act of 1934 (Amendment No. )

Filed by the Registrant Filed by a Party other than the Registrant      

CHECK THE APPROPRIATE BOX:
  Preliminary Proxy Statement
Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
Definitive Proxy Statement
  Definitive Additional Materials
Soliciting Material Under Rule 14a-12

CVS Health Corporation

(Name of Registrant as Specified In Its Charter)
(Name of Person(s) Filing Proxy Statement, if Other Than the Registrant)

PAYMENT OF FILING FEE (CHECK THE APPROPRIATE BOX):
  No fee required.
Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.
1) Title of each class of securities to which transaction applies:
2) Aggregate number of securities to which transaction applies:
3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):
4) Proposed maximum aggregate value of transaction:
5) Total fee paid:
Fee paid previously with preliminary materials:
Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the form or schedule and the date of its filing.
1) Amount previously paid:
2) Form, Schedule or Registration Statement No.:
3) Filing Party:
4) Date Filed:


Table of Contents

Notice of
Annual Meeting
of Stockholders

June 4, 2018; 8:00 a.m.

CVS Health Corporation
Customer Support Center
One CVS Drive
Woonsocket, Rhode Island 02895


Table of Contents

Message from Our Chairman and
Our Chief Executive Officer

Dear Fellow Stockholders:

CVS Health remains a preeminent health care company, uniquely positioned to deliver more affordable, accessible, and effective care. Through our unique suite of enterprise assets, we can deliver value to all health care stakeholders and help them to better realize their health care goals.

Overall 2017 Performance
We must acknowledge that our growth in 2017 was less than levels to which we and our stockholders have been accustomed. While we delivered earnings in line with expectations, those expectations were low, driven primarily by the loss of retail pharmacy prescriptions associated with pharmacy network changes. As a result, net revenues grew 4% and adjusted earnings per share increased by 1%. To combat these headwinds, we implemented a four-point plan to return us to healthier levels of earnings growth over the coming years. We are pleased to report that we have been successfully executing against this plan, and 2018 is expected to build upon that success as we continue on our path to more robust growth.

Our Use of Capital and the Pending Aetna Merger
We generated substantial cash flow and utilized it to deliver on our three-pillared approach to capital allocation and enhance returns to our stockholders. We optimize our capital allocation through dividends, share repurchases, and by investing in high-return, value-enhancing projects. Through this effective approach, in 2017, we returned more than $6 billion to stockholders through dividends and share repurchases. Additionally, we announced the proposed acquisition of Aetna, a leading diversified health care benefits company. We expect that our combined companies will remake the consumer health care experience by creating a new platform that puts the consumer at the center of health care delivery, enabling care that is easier to use and less expensive. This acquisition, which has already received the approval of both companies’ stockholders, is expected to unlock long-term value that further advances our return to robust growth, and it positions the combined company as America's front door to quality health care. We look forward to garnering regulatory approval, closing the transaction, and beginning our work to better address the challenges in the U.S. health care system.

Corporate Social Responsibility
At CVS Health, we are guided by our purpose of helping people on their path to better health and nowhere is this more apparent than our corporate social responsibility roadmap, Prescription for a Better World. This roadmap focuses on three key priorities: playing an active role in supporting health and wellness, reducing the environmental impact of our footprint, and striving to create a safe, rewarding, engaging, and inclusive workplace. Notably, last year we rolled out a series of enterprise initiatives to help fight the national opioid abuse epidemic aligned with the U.S. Centers for Disease Control and Prevention’s guideline. You can find highlights of our progress on these initiatives inside the back cover of this proxy statement.


Corporate Governance
We remain committed to sound corporate governance practices and a critical element of that is an ongoing dialogue with our stockholders. Over the past year, we have proactively engaged with many stockholders to help us understand their needs and concerns, and we listened to their suggestions on how to improve our corporate governance decision-making process. Within this proxy statement, you will find the details of the changes we have made in response to these conversations. Particularly exciting are the changes we are making to better align compensation with performance, which are laid out in the letter from the Management Planning and Development Committee. We welcome feedback from you regarding future improvements.

Annual Meeting of Stockholders
Our 2018 Annual Meeting of Stockholders will be held on Monday, June 4, 2018, at 8:00 a.m., at the CVS Health Customer Support Center located at One CVS Drive in Woonsocket, Rhode Island. We invite you to attend, and ask you to please vote at your earliest convenience, whether or not you plan to attend. Your vote is important.

Thank you for your interest and investment in CVS Health. We appreciate your continued support as we look to take a larger role in the health of our country with the vision of a better, brighter, and healthier future.

Sincerely,

     
David W. Dorman Larry J. Merlo
Chairman of the Board President and Chief Executive Officer

cvshealthannualmeeting.com 01


Table of Contents

   

Table of Contents

Message from Our Chairman and Our Chief Executive Officer       01
 
Notice of Annual Meeting of Stockholders 03
 
Proxy Statement Highlights 04
 
Corporate Governance and Related Matters 09
 Item 1:  Election of Directors 09
The Board’s Role and Activities in 2017 17
Board Structure and Processes 20
Committees of the Board 21
Board Meetings and Attendance 27
Non-Employee Director Compensation 27
 
Audit Committee Matters 29
 Item 2:  Ratification of Appointment of Independent Registered Public Accounting Firm 29
 
Executive Compensation and Related Matters 31
 Item 3:  Say on Pay, a Proposal to Approve, on an Advisory Basis, the Company’s Executive Compensation 31
Letter from the Management Planning and Development Committee 33
 
Report of the Compensation Committee 33
Compensation Discussion and Analysis 34
Summary 34
Business and Performance Highlights 38
Detailed Program Discussion 39
 
Executive Compensation Tables 54
Summary Compensation Table 54
Grants of Plan-Based Awards 56
Outstanding Equity Awards at Fiscal Year-End 57
Option Exercises and Stock Vested 58
Pension Benefits 58
Nonqualified Deferred Compensation 59
Payments/(Forfeitures) Under Termination Scenarios 60
 
CEO Pay Ratio 64
Additional Management Proposal 65
 Item 4:  Proposal to Approve an Amendment to the Company’s Certificate of Incorporation 65
 
Stockholder Proposal 66
 Item 5:  Stockholder Proposal Regarding Executive Pay Confidential Voting 66
 
Ownership of and Trading in our Stock 68
Executive Officer and Director Stock Ownership Requirements 68
Share Ownership of Directors and Certain Executive Officers 69
Share Ownership of Principal Stockholders 70
Section 16(a) Beneficial Ownership Reporting Compliance 70
 
Other Information 71
Information About the Annual Meeting and Voting 71
Stockholder Proposals and Other Business for Our Annual Meeting in 2019 73
Other Matters 73
 
Exhibit A - Amendment to the Company’s Certificate of Incorporation A-1

02 2018 Proxy Statement


Table of Contents

   

Notice of Annual Meeting of Stockholders

Date and Time
June 4, 2018, 8:00 A.M.
     
Place
CVS Health Corporation
Customer Support Center
One CVS Drive
Woonsocket, Rhode Island 02895

Items to be Voted
Elect 12 directors named in this proxy statement;
 
Ratify the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for fiscal 2018;
 
Say on pay, an advisory vote to approve the Company’s executive compensation;
 
Act to approve an amendment to the Company’s Certificate of Incorporation to reduce the ownership threshold for our stockholders’ right to call special meetings;
 
Act on one stockholder proposal, if properly presented; and
 
Conduct any other business properly brought before the Annual Meeting.

Eligibility to Vote
Stockholders of record at the close of business on April 10, 2018 may vote at the Annual Meeting.

By Order of the Board of Directors,


Colleen M. McIntosh
Senior Vice President & Corporate Secretary

          
         
 

How to Vote
Your vote is important to the future of CVS Health. You are eligible to vote if you were a stockholder of record at the close of business on April 10, 2018. Even if you plan to attend the Annual Meeting, please vote as soon as possible using one of the following methods. In all cases, you should have your proxy card in hand:

     

Use the Internet
www.proxyvote.com

 

Use a Mobile Device
Scan this QR Code

 

Call Toll-Free
1-800-690-6903

 

Mail Your Proxy Card
Follow the instructions on your voting form

 

Important Notice Regarding the Availability of Proxy Materials for the Annual Meeting to Be Held on June 4, 2018:

The proxy statement and annual report to security holders are available at www.cvshealthannualmeeting.com and at www.proxyvote.com/cvs.

 

Your vote is important.

Whether or not you plan to attend the Annual Meeting, please vote your shares. In addition to voting in person or by mail, stockholders of record have the option of voting by telephone or via the Internet. If your shares are held in the name of a bank, broker or other holder of record (i.e., in “street name”), please read your voting instructions to see which of these options are available to you. Even if you are attending the Annual Meeting in person, we encourage you to vote in advance by mail, phone or Internet.

We began mailing and made available this proxy statement and proxy card on or about April 25, 2018 to all stockholders entitled to vote. Our 2017 Annual Report, which includes our financial statements, is being sent with this proxy statement.

cvshealthannualmeeting.com 03


Table of Contents

   

Proxy Statement Highlights

This summary highlights selected information in this Proxy Statement – please review the entire document before voting.

All of our Annual Meeting materials are available in one place at www.cvshealthannualmeeting.com. There, you can download electronic copies of our Annual Report and Proxy Statement, and use the link to vote.

Voting Items

      Board Recommendation       Further information
ITEM 1
Election of directors

 each director nominee

      pages 9-17      

Our directors are seasoned leaders who bring a mix of skills and qualifications to the Board

 

ITEM 2

     pages 29-30     

Ratify the appointment the Company’s independent registered public accounting firm for 2018

Based on its recent evaluation, our Audit Committee believes that the retention of Ernst & Young is in the best interests of the Company and its stockholders

ITEM 3

     pages 31-32     

Say on pay - an advisory vote on the approval of the Company's executive compensation

Our executive compensation program reflects our unwavering commitment to paying for performance and reflects feedback received from stockholder outreach

ITEM 4

        page 65        

Approve an amendment to the Company’s Certificate of Incorporation to reduce the ownership threshold for our stockholders’ right to call special meetings

We believe that a lower threshold is consistent with the advisory vote of a majority of stockholders who voted at the 2017 annual meeting

ITEM 5

     pages 66-67     

Stockholder proposal regarding executive pay confidential voting

The proposed by-law would restrict our ability to engage with our stockholders and it is unnecessary because stockholders already have the ability to keep their votes confidential


04 2018 Proxy Statement


Table of Contents

Proxy Statement Highlights

The CVS Health Board

You are asked to vote on the election of the following 12 nominees to serve on the Board of Directors of CVS Health. All directors are elected by a majority of votes cast, and all presently serve on the CVS Health Board.

CVS Health Committees
Name, Primary Occupation     Age     Director
Since
    Independent     Other
Public
Company
Boards
    A     MP&D     N&CG     PS&CQ     E
Richard M. Bracken
Retired Chairman and CEO of HCA Holdings, Inc.
65 2015 YES None
C. David Brown II
Chairman of Broad and Cassel
66 2007 YES 1
Alecia A. DeCoudreaux
Retired President of Mills College and
Former Executive at Eli Lilly & Company
63 2015 YES None
Nancy-Ann M. DeParle
Co-Founding Partner of Consonance
Capital Partners, LLC
61 2013 YES 1
David W. Dorman
Chair of the Board of CVS Health Corporation;
Former Chairman and CEO of AT&T Corporation
64 2006 YES 1
Anne M. Finucane
Vice Chairman, Executive Management Team of
Bank of America Corporation
65 2011 YES None
Larry J. Merlo
President and CEO of CVS Health Corporation
62 2010 NO None
Jean-Pierre Millon
Retired President and CEO of PCS Health
Systems, Inc.
67 2007 YES None
Mary L. Schapiro
Vice Chair, Advisory Board Promontory
Financial Group
62 2017 YES 1
Richard J. Swift
Retired Chairman of the Board, President and
CEO of Foster Wheeler Ltd.
73 2006 YES 4
William C. Weldon
Retired Chairman of the Board and CEO of
Johnson & Johnson
69 2013 YES 2
Tony L. White
Retired Chairman of the Board, President and
CEO of Applied Biosystems, Inc.
71 2011 YES 1

: Committee Chair                                      MP&D: Management Planning & Development                                      PS&CQ: Patient Safety & Clinical Quality
A: Audit N&CG: Nominating & Corporate Governance E: Executive

cvshealthannualmeeting.com 05


Table of Contents

Proxy Statement Highlights

Selecting Our Directors

                               
                       
Director Independence       Director Gender       Director Tenure

11 directors, including our Chair, are independent of CVS Health. Mr. Merlo, our President and CEO, is our only non-independent director.

Three of the last four additions to our Board are women.

Our directors bring a balance of experience and fresh perspective to our boardroom. The average tenure of our directors is seven years.


Born Outside of the U.S.       Financial Expertise

Our directors come from varied backgrounds, including 8 different states and two foreign countries.

Three members of our Audit Committee are designated Audit Committee Financial Experts. Five other board members have qualifications to be financial experts, and the remainder are financially literate.

Director Skills and Experience

Our directors possess relevant experience, skills and qualifications that contribute to a well-functioning Board to effectively oversee the Company’s strategy and management. Areas of director expertise include:

6/12                          

9/12                          

8/12                          

Business Development and
Corporate Transactions
     Health Care and Regulated Industries      Public Company Board Service
 

4/12

4/12

5/12

Business Operations International Business Operations Public Policy and Government Affairs
 

7/12

8/12

9/12

Corporate Governance

Leadership (Current or Former CEOs)

Risk Management

 

9/12

4/12

3/12

Finance

Legal and Regulatory Compliance

Technology and Innovation


06 2018 Proxy Statement


Table of Contents

Proxy Statement Highlights

Board and Corporate Governance Highlights

The CVS Health Board continues to evaluate the Company’s corporate governance policies and practices to ensure that the right mix of individuals are present in our boardroom and to best serve the stockholders we represent by ensuring effective oversight of our strategy and management. We are committed to maintaining the highest standards of corporate governance, and have established a strong and effective framework by which the Company is governed and reviewed.

        Further Information
2017-2018 Board and Corporate Governance Developments
In May 2017 Mary Schapiro was elected to our Board of Directors, strengthening our Board's financial expertise and increasing its gender diversity
page 14
The Board is proposing a reduction in the threshold for our stockholders’ right to call special meetings of stockholders, from 25% of shares outstanding to 15%, following an advisory vote by stockholders of 52% in favor of this reduction in 2017
page 19
Key corporate governance documents, including the Certificate of Incorporation, By-laws, Corporate Governance Guidelines and Committee Charters, were updated and harmonized
page 23
Board Communication and Stockholder Rights
Our Board supports our stockholder outreach program and has responded to stockholder input with changes in our compensation program and other areas
pages 8 and 19
Right to act by written consent and to call special meetings
page 65
Majority voting in director elections
page 16
Proxy access by-law
page 17
Annual election of all directors, annual “say-on-pay” vote
pages 9, 34-35
Director Alignment with Stockholder Interests
At least 75% of our directors’ annual retainer mix is paid in shares of CVS Health common stock
page 28
Directors must own at least 10,000 shares of CVS Health common stock
page 68
Directors had excellent meeting attendance, averaging 97%
page 27
Board Oversight of Risk
Full Board and individual Committee focus on understanding and assessing Company risks
page 18
Annually, the Audit Committee reviews our policies and practices with respect to risk assessment and risk management, including discussing with management our major risks and the steps that have been taken to monitor and mitigate such risks
page 22
The Management Planning and Development Committee is responsible for reviewing and assessing potential risk arising from the Company’s compensation policies and practices
page 24
The Patient Safety and Clinical Quality Committee reviews and assesses risks arising from the Company’s provision of health care services across the enterprise, and the steps taken to monitor and mitigate those risks
page 26
Our independent Chair and our CEO are focused on the Company’s risk management efforts and ensure that risk matters are appropriately brought to the Board and/or its Committees for review

cvshealthannualmeeting.com 07


Table of Contents

Proxy Statement Highlights

Stockholder Outreach – Governance and Compensation Actions

In late 2017 and early 2018, we reached out to holders of more than 50% of our outstanding common stock in the aggregate, and held calls with holders of nearly 25% of our outstanding shares. We also held calls with both leading proxy advisory firms. We discussed a number of topics on these calls, including our strategy in the evolving health care industry, our Board composition and practices, special meeting rights, and our initiatives around corporate social responsibility including enhanced initiatives to help fight the national opioid abuse epidemic. We also sought feedback on our compensation program after a disappointing outcome at our 2017 annual meeting on our say on pay proposal, which received support from approximately 61% of votes cast. Our Independent Board Chair, David Dorman, or the Chair of our Management Planning and Development Committee, David Brown, participated in many of the calls with our stockholders. Feedback from these conversations was shared with the Management Planning and Development Committee and full Board, and informed the changes to our compensation program approved by the Management Planning and Development Committee in early 2018.

  What we heard       What we have done
in response
      Intended outcome and
when effective

Diversity of the Board may be improved by ensuring that diverse candidates are included in director searches

Amended our Nominating and Corporate Governance Committee Charter to specifically include a requirement for diverse candidates

Memorialize and formalize our existing practice of including diverse candidates in all director searches

Effective January 2017; Mary Schapiro nominated in March and elected in May 2017

More of your long-term compensation should be performance-based, rather than time-based

We are replacing time-based restricted stock units (RSUs) with performance share units (PSUs) subject to a three-year performance period, and shares delivered in settlement of PSUs will be subject to a two-year holding period post-vest

Further incentivizes long-term performance and ties compensation to achievement of long-term goals
Beginning with 2018 awards

The Long-Term Incentive Plan (LTIP) should be denominated in stock, and the comparator group should more closely align to the business

All LTIP grants will be denominated in PSUs that will be reported in the Summary Compensation Table in the year of grant. The comparator group for the relative performance TSR modifier under the LTIP will change from the S&P 500 to a smaller index of specified health care and consumer staples companies

Denominating awards in PSUs and reporting them in the year of grant makes the disclosure easier to understand, and changing the modifier group better aligns it to the Company’s business

Beginning with 2018-2020 award cycle

More transparency is needed for the individual component of your annual incentive plan

Added disclosure regarding the Management Planning and Development Committee’s evaluation of each executive’s goals and performance

Increases transparency in terms of annual bonus awards and further emphasizes the Management Planning and Development Committee’s pay for performance philosophy

This proxy statement

 

                                                                                
 
For more information on changes to our compensation programs, see the letter from the Management Planning and Development Committee on page 33 and the Compensation Discussion and Analysis beginning on page 34. For more information on corporate governance at CVS Health, please refer to pages 9-28 of this proxy statement and to our website at http://investors.cvshealth.com/corporate-governance.    

08 2018 Proxy Statement


Table of Contents

 

Corporate Governance and Related Matters

Item 1: Election of Directors

Our Board of Directors has nominated 12 candidates for election as directors at the Annual Meeting. All 12 nominees currently serve as directors. If elected, each nominee will hold office until the next annual meeting.

The Nominating and Corporate Governance Committee believes that the Board is well-balanced and that it fully and effectively addresses the Company’s needs. All of our nominees are seasoned leaders, the majority of whom are or were chief executive officers or other senior executives, who bring to the Board skills and qualifications gained during their tenure at a vast array of public companies, private companies, non-profits, governmental and regulatory agencies and other organizations. We have indicated below for each nominee certain of the experience, qualifications, attributes or skills that led the Committee and the Board to conclude that the nominee should continue to serve as a director. Please note that each director possesses qualifications in addition to those listed under their name; we have only listed the core attributes considered by the Board to be most relevant to each nominee.

                   
   

The Board of Directors unanimously recommends a vote ✓ FOR  the election of all director nominees.

2017 Board of Directors

1 Richard Bracken 2 Anne Finucane 3 Richard Swift 4 Nancy-Ann DeParle 5 Tony White 6 Larry Merlo
7 David Dorman 8 Jean-Pierre Millon 9 William Weldon 10 Mary Schapiro 11 David Brown 12 Alecia DeCoudreaux

                                                                            
 
    For more information about our directors, please refer to pages 10-21 of this proxy statement.    

cvshealthannualmeeting.com 09


Table of Contents

Corporate Governance and Related Matters: Item 1

Biographies of our Incumbent Board Nominees
Richard M. Bracken
Retired Chairman and CEO
of HCA Holdings, Inc.
Independent Director
CVS Health Board
Committees
Patient Safety
and Clinical Quality (Chair);
Nominating and Corporate
Governance; Executive
Other Public Boards
None
Age 65
Director since
January 2015
Director Qualification Highlights
Leadership – Former CEO
Business Operations; Consumer Products and Services
Finance
Health Care/Regulated Industry
Risk Management
Corporate Governance
Education B.A., San Diego State University; M.H.A., Medical College of Virginia, Virginia Commonwealth University
Biography Mr. Bracken is the former Chairman and Chief Executive Officer of HCA Holdings, Inc., one of the nation’s leading providers of health care services. At the time of Mr. Bracken’s retirement, HCA’s facilities included approximately 165 hospitals and 115 freestanding surgery centers in 20 states and England. Mr. Bracken served in a number of executive roles in his 33 year career at HCA, including President of HCA’s Pacific Division in 1995, Western Group President in 1997, Chief Operating Officer of HCA in July 2001, and President and Chief Operating Officer in January 2002. He was elected to the HCA Board of Directors in November 2002, became President and Chief Executive Officer in January 2009, and Chairman and Chief Executive Officer in December, 2009. He retired as CEO in December 2013, and as Chairman in December 2014.
Skills and Qualifications of Particular Relevance to CVS Health Mr. Bracken’s experience in leading a large, publicly traded health care company lends expertise and perspective greatly valued by the Board. In addition, his experience operating in the highly-regulated health care industry with significant experience in enterprise clinical quality is also a complementary skill set for the Board. That experience led the Board to appoint Mr. Bracken as Chair of the Patient Safety and Clinical Quality Committee when it was formed in March 2016.
C. David Brown II
Chairman of Broad and Cassel
Independent Director
CVS Health Board Committees
Management Planning and
Development (Chair); Nominating
and Corporate Governance;
Executive
Other Public Boards
Rayonier Advanced
Materials Inc.
Age 66
Director since
March 2007
Director Qualification Highlights
Business Operations; Real Estate
Business Development, Corporate Strategy and Transactions
Finance
Legal and Regulatory Compliance
Health Care/Regulated Industry
Risk Management
Public Company Board Service
Education B.S.B.A., University of Florida; J.D., University of Florida College of Law
Biography Mr. Brown has been Chairman of Broad and Cassel, a Florida law firm, since March 2000. From 1989 until March 2000, he was Managing Partner of the Orlando office of the firm. He is also the lead director of Rayonier Advanced Materials Inc. (RYAM), a leading specialty cellulose production company. Mr. Brown previously served on the board of directors and as lead director of Rayonier Inc., a real estate development and timberland management company, prior to the spin-off of RYAM in June 2014. He also served as a director of ITT Educational Services, Inc., a national provider of technology-oriented degree programs, from April 2015 until September 2016. Mr. Brown previously served on the board of Caremark Rx, Inc. from March 2001 until the closing of the merger transaction involving CVS Health and Caremark, when he became a director of CVS Health.
Skills and Qualifications of Particular Relevance to CVS Health Mr. Brown’s legal expertise and health care experience are highly valued by the Board, as is his ability to analyze and interpret complex issues and facilitate Board engagement. Mr. Brown has significant health care experience, including through his oversight of UF Health while serving as Chairman of the Board of Trustees for the University of Florida and as a member of the Board of Directors and Executive Committee of Orlando Health, a not-for-profit health care network. The Board believes that Mr. Brown’s experience adds knowledge and leadership depth to the Board.


10 2018 Proxy Statement


Table of Contents

Corporate Governance and Related Matters: Item 1

Alecia A. DeCoudreaux
Retired President of Mills
College and Former Executive at
Eli Lilly & Company
Independent Director
CVS Health Board
Committees
Audit; Patient
Safety and Clinical Quality
Other Public Boards
None
Age 63
Director since
March 2015
Director Qualification Highlights
Business Development, Corporate Strategy and Transactions
Legal and Regulatory Compliance
Health Care/Regulated Industry
Corporate Governance
Risk Management
Public Policy and Government Affairs
Education B.A., Wellesley College; J.D., Indiana University School of Law
Biography Ms. DeCoudreaux is the former President of Mills College, a liberal arts college for women with graduate programs for women and men, having served a five-year term in that position from July 2011 through June 2016. Previously, Ms. DeCoudreaux served in a number of leadership roles at Eli Lilly and Company, a global pharmaceutical manufacturer, including as Vice President and Deputy General Counsel, Specialty Legal Team, from 2010-2011, Vice President and General Counsel, Lilly USA, from 2005-2009, and Secretary and Deputy General Counsel of Eli Lilly from 1999-2005. During her 30-year career with Eli Lilly Ms. DeCoudreaux also previously served as Executive Director of Lilly Research Laboratories, Director of Federal Government Relations, Director of State Government Relations and Director of Community Relations. In addition, Ms. DeCoudreaux has served on a number of charitable, educational, for profit and nonprofit boards, including as both a trustee and board chair at Wellesley College.
Skills and Qualifications of Particular Relevance to CVS Health Ms. DeCoudreaux has more than 30 years of experience in the pharmaceutical industry, and her experience as an attorney in that field and in the area of corporate governance, makes her a great asset to our Board.
Nancy-Ann M. DeParle
Co-Founding Partner
of Consonance Capital
Partners, LLC
Independent Director
CVS Health Board
Committees
Audit; Patient
Safety and Clinical Quality
Other Public Boards
HCA Holdings, Inc.
Age 61
Director since
September 2013
Director Qualification Highlights
Business Development, Corporate Strategy and Transactions
Finance
Legal and Regulatory Compliance
Health Care / Regulated Industry
Public Policy and Government Affairs
Public Company Board Service
Education B.A., University of Tennessee; B.A. and M.A., Balliol College, Oxford University; J.D., Harvard Law School
Biography Ms. DeParle has been a Co-Founding Partner of Consonance Capital Partners, LLC, a private equity firm focused on investing in small and mid-size health care companies, since August 2013. From March 2009 to January 2013, Ms. DeParle served in the White House, first as Counselor to the President and Director of the White House Office of Health Reform, and later as Assistant to the President and Deputy Chief of Staff for Policy. In addition, from 1993 to 2000, Ms. DeParle served as the Associate Director for Health and Personnel for the White House Office of Management and Budget, and later as the Administrator of the Centers for Medicare and Medicaid Services (then known as the Health Care Financing Administration). From 2001 to March 2009, Ms. DeParle served as a Senior Advisor with JPMorgan Partners and as a Managing Director of its successor entity, CCMP Capital, L.L.C., focusing on private equity investments in health care companies. Ms. DeParle is also a director of HCA Holdings, Inc., a health care services company that owns, manages or operates hospitals and various other health care facilities.
Skills and Qualifications of Particular Relevance to CVS Health Ms. DeParle has more than 25 years of experience in the health care arena, and is widely considered to be one of the nation’s leading experts in health care policy, management and financing, which makes her an excellent fit for our Board.


cvshealthannualmeeting.com 11


Table of Contents

Corporate Governance and Related Matters: Item 1

David W. Dorman
Chairman of the Board of CVS
Health Corporation, Former
Chairman and CEO of AT&T
Corporation, and Founding
Partner of Centerview Capital
Technology Fund
Independent Director
CVS Health Board
Committees
Management
Planning and Development;
Nominating and Corporate
Governance (Chair); Executive
Other Public Boards
PayPal Holdings, Inc.
Age 64
Director since
March 2006
Director Qualification Highlights
Leadership – Former CEO
Finance
International Business Operations; Consumer Products or Services
Technology and Innovation
Risk Management
Corporate Governance
Public Company Board Service
Education B.S., Georgia Institute of Technology
Biography Mr. Dorman has been the Chairman of the Board of CVS Health Corporation since May 2011. He has also been a Founding Partner of Centerview Capital Technology Fund, a private investment firm, since July 2013. He also served as Lead Director of Motorola Solutions, Inc. (formerly Motorola, Inc.), a communications products company, until his retirement from that board in May 2015, and was Non-Executive Chairman of the Board of Motorola from May 2008 through May 2011. From October 2006 through April 2008, he was a Managing Director and Senior Advisor with Warburg Pincus LLC, a global private equity firm. From November 2005 until January 2006, Mr. Dorman served as President and a director of AT&T Inc., a telecommunications company (formerly known as SBC Communications). From November 2002 until November 2005, Mr. Dorman was Chairman of the Board and Chief Executive Officer of AT&T Corporation. Mr. Dorman is also a director of PayPal Holdings, Inc., a leading digital and mobile payments company, as well as Dell Technologies Inc., the world’s largest privately controlled technology company. He was also a director of SecureWorks Corp., an information security solutions provider and a subsidiary of Dell, from the time of SecureWorks’ IPO in April 2016 until he joined the board of Dell in September 2016. He was a director of Yum! Brands, Inc., a global quick service restaurant company, from 2005 until his retirement from that board in May 2017.
Skills and Qualifications of Particular Relevance to CVS Health Mr. Dorman’s experience in leading large companies, beginning with Sprint and later Pacific Bell and AT&T, lends a perspective and skill set that is greatly valued by the Board. His business background of growing companies is in line with and useful to our business strategy. The Board believes that Mr. Dorman’s experience leading the boards of AT&T and Motorola make him well-suited to be the Company’s Chairman.
Anne M. Finucane
Vice Chairman and Member of
Executive Management Team of
Bank of America Corporation
Independent Director
CVS Health Board
Committees
Nominating
and Corporate Governance;
Management Planning and
Development
Other Public Boards None
Age 65
Director since
January 2011
Director Qualification Highlights
Business Operations; Consumer Products or Services
Business Development, Corporate Strategy and Transactions
Public Policy and Government Affairs
Regulated Industry
Corporate Governance
Risk Management
Education B.A., University of New Hampshire
Biography Ms. Finucane has been Vice Chairman of Bank of America Corporation, an international financial services company, since July 2015 and is a member of its executive management team. From 2006 through July 2015 Ms. Finucane served as Global Chief Strategy and Marketing Officer for Bank of America and served as Northeast Market President from 2004 through July 2015. During her twenty-plus years as a senior leader at Bank of America and its legacy firms, Ms. Finucane has served as senior advisor to four chief executive officers and the Board of Directors. Ms. Finucane is responsible for the strategic positioning of Bank of America and oversees the public policy, customer research and analytics, global marketing, communications and corporate social responsibility efforts for the company. She is chair of Bank of America’s Environmental, Social and Governance Committee, and is also chair of the Bank of America Charitable Foundation.
Skills and Qualifications of Particular Relevance to CVS Health Ms. Finucane’s experience in the financial services industry, consumer policy, strategy, marketing, corporate social responsibility and government affairs provides the Board with valuable insight in those key areas.



12 2018 Proxy Statement


Table of Contents

Corporate Governance and Related Matters: Item 1

Larry J. Merlo
President and Chief Executive
Officer of CVS Health
Corporation
Non-Independent Director
CVS Health Board
Committees
Executive
Other Public Boards None
Age 62
Director since
May 2010
Director Qualification Highlights
Leadership – Current CEO
Business Operations; Consumer Products or Services
Business Development, Corporate Strategy and Transactions
Health Care/Regulated Industry
Real Estate
Public Policy and Government Affairs
Pharmacy Benefit Management
Education B.S., Pharmacy, University of Pittsburgh
Biography Mr. Merlo has been Chief Executive Officer of CVS Health Corporation since March 2011 and President of CVS Health Corporation since May 2010. Mr. Merlo formerly served as Chief Operating Officer of CVS Health Corporation from May 2010 through March 2011 and was President of CVS Pharmacy from January 2007 through May 2010, and Executive Vice President – Stores from April 2000 to January 2007.
Skills and Qualifications of Particular Relevance to CVS Health Mr. Merlo has been with CVS Health and its subsidiaries for nearly 40 years, and provides the Board with invaluable experience and insight into the retail drugstore and health care industries.
Jean-Pierre Millon
Retired President and Chief
Executive Officer of PCS Health
Systems, Inc.
Independent Director
CVS Health Board
Committees
Audit; Patient
Safety and Clinical Quality
Other Public Boards None
Age 67
Director since
March 2007
Director Qualification Highlights
Leadership – Former CEO
Finance
Business Development, Corporate Strategy and Transactions
Health Care/Regulated Industry
International Business Operations
Pharmacy Benefit Management
Public Company Board Service
Education B.S., Ecole Centrale de Lyon (France); B.A., Université de Lyon (France); M.B.A., Kellogg School of Business, Northwestern University
Biography Mr. Millon is the retired former President and Chief Executive Officer of PCS Health Systems, Inc. Mr. Millon joined PCS in 1995, where he served as President and Chief Executive Officer from June 1996 until his retirement in September 2000. Prior to that, Mr. Millon served as an executive and held several global leadership positions with Eli Lilly and Company. Mr. Millon previously served on the board of Caremark from March 2004, upon Caremark’s acquisition of AdvancePCS, and as a director of AdvancePCS (which resulted from the merger of PCS and Advance Paradigm, Inc.) beginning in October 2000. He became a director of CVS Health upon the closing of the merger transaction involving CVS Health and Caremark. Mr. Millon has over 10 years of financial management experience and fifteen years of general functional management experience, including strategic planning experience specific to pharmacy benefit management companies as the former head of PCS. He also has extensive venture capital and public and private company board experience.
Skills and Qualifications of Particular Relevance to CVS Health Mr. Millon’s extensive background and experience in the pharmacy benefit management, pharmaceutical and life sciences businesses, combined with his financial expertise, provide the Board with additional perspective across the enterprise.


cvshealthannualmeeting.com 13


Table of Contents

Corporate Governance and Related Matters: Item 1

Mary L. Schapiro
Vice Chair of the Advisory
Board Promontory Financial
Group
Independent Nominee
CVS Health Board
Committees
Audit
Other Public Boards
London Stock Exchange
Group plc
Age 62
Director since
May 2017
Director Qualification Highlights
Leadership – Former CEO
Public Policy and Government Affairs
Finance
Risk Management
Legal and Regulatory Compliance
Public Company Board Service
Education B.A., Franklin and Marshall College; J.D., George Washington University
Biography Since January 2014, Ms. Schapiro has served as the Vice Chair of Promontory Advisory Board, part of Promontory Financial Group, a leading strategy, risk management and regulatory compliance firm that was acquired by IBM Corporation in November 2016. She previously served as managing director of Promontory Financial Group from March 2013 through January 2014. From January 2009 through December 2012, Ms. Schapiro was Chairman of the U.S. Securities and Exchange Commission, becoming the first woman to serve as that agency’s Chairman. Prior to becoming SEC Chairman, Ms. Schapiro was Chairman and CEO of the Financial Industry Regulatory Authority (FINRA) from 2006 through 2008, and prior to that held a number of key executive positions at FINRA and its predecessor from 1996 through 2006, including Vice Chairman and President of NASD Regulation. She also served as Chairman of the Commodity Futures Trading Commission (CFTC) from 1994 to 1996, and was the only person to serve as Chairman of both the CFTC and the SEC. Ms. Schapiro is also a director of The London Stock Exchange Group plc, which engages in market infrastructure and the capital markets business. Ms. Schapiro was also a director of General Electric Company (GE), a global diversified infrastructure company, from April 2013 until her retirement from that board effective at the time of GE’s April 2018 annual meeting.
Skills and Qualifications of Particular Relevance to CVS Health Ms. Schapiro’s experience in leading the SEC, FINRA and the CFTC makes her extremely well qualified to serve on our Board. Ms. Schapiro’s leadership of the SEC during the turbulent period that followed the 2008 financial crisis, one of the busiest rulemaking periods in the agency’s history, demonstrates her ability to navigate through a difficult and complex regulatory and political environment. The Board believes that her skills fill important needs in the areas of legal and regulatory compliance, finance, risk management, and public policy and government affairs.
Richard J. Swift
Retired Chairman of the Board,
President and Chief Executive
Officer of Foster Wheeler Ltd.
Independent Director
CVS Health Board
Committees
Audit (Chair);
Executive
Other Public Boards Ingersoll-
Rand plc, Kaman Corporation,
Hubbell Incorporated, Public
Service Enterprise Group
Incorporated
Age 73
Director since
September 2006
Director Qualification Highlights
Leadership – Former CEO
Finance
International Business Operations
Technology and Innovation
Risk Management
Corporate Governance
Public Company Board Service
Education B.S., U.S. Military Academy at West Point; M.S., Purdue University; M.B.A., Fairleigh Dickinson University
Biography Mr. Swift is the former Chairman of the Board, President and Chief Executive Officer of Foster Wheeler Ltd., an international engineering and construction firm, having served in those positions from April 1994 until his retirement in October 2001. Mr. Swift also served as a member and as Chairman of the Financial Accounting Standards Advisory Council (FASAC) from 2002 until his retirement from FASAC in December 2006. Mr. Swift is also lead director of Ingersoll-Rand plc, a diversified industrial company, and a director of Kaman Corporation, a diversified manufacturer and distributor, Hubbell Incorporated, an electrical and electronic products company, and Public Service Enterprise Group Incorporated, an energy company.
Skills and Qualifications of Particular Relevance to CVS Health The Board greatly values Mr. Swift’s financial expertise, including his experience at FASAC and with various public company boards and audit committees for over 30 years of combined service. Mr. Swift is an audit committee financial expert and his accounting and financial skills are important to the oversight of our financial reporting, enterprise and operational risk management.



14 2018 Proxy Statement


Table of Contents

Corporate Governance and Related Matters: Item 1

William C. Weldon
Retired Chairman of the
Board and Chief Executive Officer of
Johnson & Johnson
Independent Director
CVS Health Board
Committees
Management
Planning and Development,
Nominating and Corporate
Governance
Other Public Boards
JPMorgan Chase & Co., Exxon
Mobil Corporation
Age 69
Director since
March 2013
Director Qualification Highlights
Leadership – Former CEO
Finance
Health Care/Regulated Industry
International Business Operations; Consumer Products or Services
Risk Management
Corporate Governance
Public Company Board Service
Education B.S., Quinnipiac University
Biography Mr. Weldon is the former Chairman of the Board and Chief Executive Officer of Johnson & Johnson, a global developer and manufacturer of health care products, having served in those positions from 2002 until his retirement as Chief Executive Officer in April 2012 and his retirement from the board in December 2012. Mr. Weldon previously served in a variety of senior executive positions during his 41-year career with Johnson & Johnson. Mr. Weldon is also a director of JPMorgan Chase & Co., a global financial services company, and Exxon Mobil Corporation, an international oil and gas company. He was formerly a director of The Chubb Corporation, an international insurance company, until it was acquired by ACE Limited in January 2016.
Skills and Qualifications of Particular Relevance to CVS Health Mr. Weldon’s experience in managing a complex global health care company and his deep knowledge of the worldwide health care market across multiple sectors makes him extremely well suited to serve on our Board. His background in international business management and operating in the highly-regulated health care industry is also greatly valued by the Board.

Tony L. White
Retired Chairman of the
Board, President and Chief
Executive Officer of Applied
Biosystems, Inc.
Independent Director
CVS Health Board
Committees
Management
Planning and Development;
Patient Safety and Clinical
Quality
Other Public Boards
Ingersoll-Rand plc
Age 71
Director since
March 2011
Director Qualification Highlights
Leadership – Former CEO
Finance
Health Care/Regulated Industry
Technology and Innovation
Risk Management
Corporate Governance
Public Company Board Service
Education B.A., Western Carolina University
Biography Mr. White is the former Chairman of the Board, President and Chief Executive Officer of Applied Biosystems, Inc. (formerly Applera Corporation), a developer, manufacturer and marketer of life science systems and genomic information products, having served in those positions from September 1995 until his retirement in November 2008. Mr. White is also a director of Ingersoll-Rand plc, a diversified industrial company. He was a director of C.R. Bard, Inc. (Bard), a company that designs, manufactures and sells medical, surgical, diagnostic and patient care devices, from 1996 until Bard was acquired by Becton Dickinson and Company in December 2017.
Skills and Qualifications of Particular Relevance to CVS Health Mr. White’s wealth of management experience in the life sciences and health care industries, including over 13 years as Chairman and CEO of an advanced-technology life sciences company and 26 years in various management positions at Baxter International, Inc., a provider of medical products and services, makes him well qualified to serve as a director of CVS Health.

cvshealthannualmeeting.com 15


Table of Contents

Corporate Governance and Related Matters: Item 1

Director Qualification Criteria; Diversity

Recognizing that the selection of qualified directors is complex and crucial to the long-term success of the Company, the Nominating and Corporate Governance Committee has established in its charter guidelines for the identification and evaluation of candidates for membership on the Board. Under its charter, the Committee recommends to the Board criteria for Board membership and recommends individuals for membership on our Board. The criteria used by the Committee in nominating directors are found in the Committee’s charter and provide that candidates should be distinguished individuals who are prominent in their fields or otherwise possess exemplary qualities that will enable them to effectively function as directors. While the Committee does not believe it appropriate to establish any specific minimum qualifications for candidates, it focuses on the following qualities in identifying and evaluating candidates for Board membership:

Background, experience and skills
   
Character, reputation and personal integrity
   
Judgment
   
Independence
   
Diversity
   
Commitment to the Company and service on the Board
   
Any other factors that the Committee may determine to be relevant and appropriate

The Committee makes these determinations in the context of the existing composition of the Board so as to achieve an appropriate mix of characteristics. Consistent with this philosophy, the Committee is committed to including in each search qualified candidates who reflect diverse backgrounds, including diversity of gender and race. The Committee also takes into account all applicable legal, regulatory and stock exchange requirements concerning the composition of the Board and its committees. The Committee reviews these guidelines from time to time as appropriate (and in any event at least annually) and modifies them as it deems appropriate.

The Committee also reviews the composition of the Board in light of the current challenges and needs of the Board and the Company, and determines whether it may be appropriate to add or remove individuals after considering, among other things, the need for audit committee expertise and issues of independence, diversity, judgment, character, reputation, age, skills, background and experience.

The Committee values diversity, which it broadly views in terms of, among other things, gender, race, background and experience, as a factor in selecting members to serve on the Board. Our nominees reflect that diversity, including in terms of race, gender and ethnic background. In addition, to ensure that it has access to a broad range of qualified, experienced and diverse candidates, the Committee may use the services of an independent search firm to help identify and assist in the evaluation of candidates.

Board Evaluation Process

When considering current directors for re-nomination to the Board, the Committee takes into account the performance of each director, which is part of the Committee’s annual Board evaluation process. That process includes individual interviews of each director by our General Counsel, followed by a report summarizing his findings. The Committee then recommends actions for the Board to consider and adopt as it sees fit.

Board Refreshment; Retirement Age

The Committee and the Board believe that setting a retirement age for CVS Health directors is advisable to facilitate the addition of new directors. Accordingly, our Corporate Governance Guidelines provide that no director who is or would be over the age of 74 at the expiration of his or her current term may be nominated to a new term, unless the Board waives the retirement age for a specific director in exceptional circumstances. In the event any waiver is provided, the Board will disclose the rationale for its decision.

Majority Voting

As discussed elsewhere in this proxy statement, directors are elected by a majority of the votes cast at the Annual Meeting (assuming that the election is uncontested). Under our by-laws, each nominee who is a current director is required to submit an irrevocable resignation, which resignation would become effective upon (1) that person not receiving a majority of the votes cast in an uncontested election, and (2) acceptance by the Board of that resignation in accordance with the policies and procedures adopted by the Board. The Board, acting on the recommendation of the Committee, will no later than at its first regularly scheduled meeting following certification of the stockholder vote, determine whether to accept the resignation of the unsuccessful incumbent. Absent a determination by the Board that a compelling reason exists for concluding that it is in the best interests of the Company for an unsuccessful incumbent to remain as a director, the Board will accept that person’s resignation. In the event any resignation is not accepted, the Board will disclose the rationale for its determination.

Stockholder Submission of Nominees

The Committee will consider any director candidates proposed by stockholders who submit a written request to our Corporate Secretary (including via our proxy access by-law, described below). All candidates should meet the Director Qualification Criteria, discussed above. The Committee evaluates all director candidates and nominees in the same manner regardless of the source. If a stockholder would like to nominate a person for election or re-election to the Board, he or she must provide notice to the Company as provided in our by-laws and described in this proxy statement. The notice must include a written consent indicating that the candidate is willing to be

16 2018 Proxy Statement


Table of Contents

Corporate Governance and Related Matters: The Board’s Role and Activities in 2017

named in the proxy statement as a nominee and to serve as a director if elected and any other information that the SEC would require to be included in a proxy statement when a stockholder submits a proposal. See “Other Information – Stockholder Proposals and Other Business for Our Annual Meeting in 2019” for additional information related to proposals, including any nominations, for our 2019 Annual Meeting.

Proxy Access

CVS Health has had a proxy access by-law since January 2016. The key terms of its proxy access by-law are:

     

A stockholder, or a group of up to 20 stockholders, owning at least 3% of the Company’s outstanding common stock continuously for at least 3 years

May nominate and include in the Company’s proxy materials director nominees constituting up to the greater of 2 nominees or 20% of the Board

Provided that the stockholders and the nominees satisfy the requirements specified in the Company’s by-laws
     

Independence Determinations for Directors

Under our Corporate Governance Guidelines, a substantial majority of our Board must be comprised of directors who meet the director independence requirements set forth in the Corporate Governance Rules of the New York Stock Exchange (NYSE) Listed Company Manual. Under NYSE Rules, no director qualifies as “independent” unless the Board affirmatively determines that the director has no material relationship with the Company.

Our Board has adopted categorical standards to assist in making director independence determinations. Any relationship that falls within the following standards or relationships will not, in itself, preclude a determination of independence. These categorical standards are set forth in Annex A to the Company’s Corporate Governance Guidelines, which are available on our website at http://investors.cvshealth.com/corporate-governance/documents or upon request to our Corporate Secretary.

2018 Determinations
The Nominating and Corporate Governance Committee of the Board undertook its annual review of director and nominee independence in March 2018. The Committee recommended and the Board determined that each of Mmes. DeCoudreaux, DeParle, Finucane and Schapiro, and each of Messrs. Bracken, Brown, Dorman, Millon, Swift, Weldon and White, is independent. Mr. Merlo is not an independent director because of his employment as President and CEO of the Company.

The Board’s Role and Activities in 2017

The Board acts as the ultimate decision-making body of the Company and advises and oversees management, which is responsible for the day-to-day operations and management of the Company. In carrying out its responsibilities, the Board reviews and assesses CVS Health’s long-term strategy and its strategic, competitive and financial performance.

CVS Health’s growth in 2017 was less robust than in recent years. While the Company delivered earnings in line with expectations, those expectations were low, driven primarily by retail prescription losses associated with pharmacy network changes. Despite these headwinds, the Board oversaw the return of approximately $6 billion to our stockholders through a combination of cash dividends and stock repurchases. The Board increased the cash dividend to $0.50 per share per quarter for 2017, and oversaw the continued execution of its $15 billion share repurchase authorization through the early part of the year. CVS Health also implemented a four-point plan to return the Company to healthier levels of earnings growth in the coming years. In December 2017, the Board approved the Company’s agreement to acquire Aetna Inc. (Aetna). The Board expects that the combination with Aetna will remake the consumer health care experience by creating a new platform that puts the consumer at the center of health care delivery, enabling care that is easier to use and less expensive. In March 2018, as part of the financing for the Aetna transaction, the Company issued $40 billion in senior bonds. In order to maintain our investment grade credit ratings, the share repurchase program and stockholder dividend increases were suspended until the Company returns to its targeted adjusted debt-to-adjusted-EBITDA ratio in the low 3x. The Board believes that the four-point plan, as well as the planned acquisition of Aetna, positions CVS Health for improved performance and will better enable us to address some of the challenges of the U.S. health care system.

The Board’s Role in Strategy and Succession Planning

The Board reviews the Company’s financial performance on a regular basis at Board meetings and through periodic updates, with a particular focus on peer and competitive comparisons. The Board also periodically reviews the Company’s long-term strategy, and assesses its strategic, competitive and financial performance, on both an absolute basis and in relation to the performance, practices and policies of its peers and competitors. While the Board receives updates regarding strategic matters throughout the year, one Board

cvshealthannualmeeting.com 17


Table of Contents

Corporate Governance and Related Matters: The Board’s Role and Activities in 2017

meeting per year, typically in September, is focused almost entirely on the Company’s short- and long-term strategic direction. The Board receives reports from management and expert speakers are often engaged. At this meeting the Board provides input and oversight on short-term strategic goals and sets the long-term strategic direction of the Company. It was at the September 2017 meeting that the Board authorized management to move forward with the proposed acquisition of Aetna.

The Board also reviews the Company’s succession planning, including succession planning in the case of the incapacitation, retirement or removal of the CEO. In that regard, the CEO provides an annual report to the Board recommending and evaluating potential successors, along with a review of any development plans recommended for such individuals. The CEO also provides to the Board, on an ongoing basis, his recommendation as to a successor in the event of an unexpected emergency. The Board also reviews succession planning with respect to the Company’s key executive officers, i.e., those who are members of the Business Planning Committee, or BPC.

The Board’s Role in Risk Oversight

The Board’s role in risk oversight involves both the full Board and its Committees, as well as members of management.

Risk Oversight Framework

Board of Directors

Focuses on understanding Company-wide risks and ensuring that risk matters are appropriately brought to the Board and/or its Committees for review.
   
Ensures that the Corporate Governance Guidelines and the Board’s leadership structure facilitate the effective oversight of risk and communication with management.
Board Committees

Each of our principal Board Committees is responsible for oversight of risk management practices for categories of risks relevant to their functions.

Audit Committee

Primary committee charged with carrying out risk oversight responsibilities on behalf of the Board, including reviewing financial, operational, compliance, reputational and strategic risks.

 
Management Planning and Development Committee Nominating and Corporate Governance Committee Patient Safety and Clinical Quality Committee
 

Management

Each major business unit is responsible for identifying risks, assessing the likelihood and potential impact of significant risks, and reporting to management’s Executive Risk Steering Committee on actions to monitor, manage and mitigate significant risks.
   
The CFO, Chief Compliance Officer and General Counsel periodically report on the Company’s risk management policies and practices to relevant Board Committees and to the full Board.

The Audit Committee is charged with the primary role in carrying out risk oversight responsibilities on behalf of the Board. Pursuant to its charter, the Audit Committee annually reviews our policies and practices with respect to risk assessment and risk management, including discussing with management the Company’s major risk exposures and the steps that have been taken to monitor and mitigate such exposures. The Audit Committee also reviews CVS Health’s major financial risk exposures as well as major operational, compliance, cybersecurity, reputational and strategic risks, including developing steps to monitor, manage and mitigate those risks.

18 2018 Proxy Statement


Table of Contents

Corporate Governance and Related Matters: The Board’s Role and Activities in 2017

Each of our other Board Committees is responsible for oversight of risk management practices for categories of risks relevant to their functions. For example, the Management Planning and Development Committee has oversight responsibility for our overall compensation structure, including review of its compensation practices, with a view to assessing associated risk. See “Compensation Risk Assessment” on page 25 for additional information.
   
As part of CVS Health’s ongoing Enterprise Risk Management process, each of our major business units is responsible for identifying risks that could affect achievement of business goals and strategies, assessing the likelihood and potential impact of significant risks, prioritizing risks and actions to be taken in mitigation and/or response, and reporting to management’s Executive Risk Steering Committee on actions to monitor, manage and mitigate significant risks.
   
Additionally, the CFO, Chief Compliance Officer and General Counsel periodically report on the Company’s risk management policies and practices to relevant Board Committees and to the full Board. The Board is regularly updated on specific risks in the course of its review of corporate strategy, business plans and reports to the Board by its respective Committees.

The Board considers its role in risk oversight when evaluating our Corporate Governance Guidelines and its leadership structure. Both the Corporate Governance Guidelines and the Board’s leadership structure facilitate the Board’s oversight of risk and communication with management. Our independent Chairman and our CEO are focused on CVS Health’s risk management efforts and ensure that risk matters are appropriately brought to the Board and/or its Committees for their review.

                   
   

The Board’s Role in Corporate Social Responsibility Oversight

The Nominating and Corporate Governance Committee of the Board of Directors, pursuant to its charter, is formally charged with oversight of the Company’s Corporate Social Responsibility (CSR) strategy and performance. The Company’s Senior Vice President of Corporate Social Responsibility and Philanthropy regularly updates the Committee on CSR risks and opportunities, and the Committee provides feedback and direction on the Company’s approach to key issues. The Committee also reviews the annual CSR Report, Prescription for a Better World, prior to its publication. It is available on the Company’s website at https://cvshealth.com/social-responsibility.

Stockholder Outreach

The Company values each of its stockholders and their opinions, and we regularly interact with our stockholders on a variety of matters. In late 2017 and early 2018, at the direction of the Board, the Company engaged in a robust stockholder outreach effort to best understand and address any concerns stockholders might have. Additional details regarding our outreach effort and the actions taken are found on pages 8 and 31 of this proxy statement.

Much of our dialogue with stockholders was focused on compensation-related matters, including the results of our most recent say-on-pay vote. The 61% vote in favor fell short of our expectations, and we received substantive feedback that resulted in changes to our compensation program. In addition to compensation-related matters, a number of corporate governance matters were discussed with our stockholders during the outreach process, including the 2017 stockholder proposal requesting a reduction in the threshold for our stockholders’ right to call special meetings of stockholders, from 25% of our outstanding stock to 15%, which received a majority of votes in favor of the proposal. After careful consideration, the Board is recommending that our stockholders approve an amendment to the Company’s Certificate of Incorporation and, following stockholder approval, will amend the Company’s By-laws to fully effectuate the requested change.

We believe that taking the responsive actions summarized above will continue to strengthen our relationships with our stockholders and provide positive improvements in the areas identified.

Contact With the Board, the Chairman and Other Independent Directors

Stockholders and other parties interested in communicating directly with the Board, the independent Chairman of the Board or with the independent directors as a group may do so by writing to them care of CVS Health Corporation, One CVS Drive, MC 1160, Woonsocket, RI 02895. The Nominating and Corporate Governance Committee has approved a process for handling letters received by the Company and addressed to the Board, the independent Chairman of the Board or to independent members of the Board. Under that process, our Corporate Secretary reviews all such correspondence and regularly forwards to the Board copies of all correspondence that, in her opinion, deals with the functions of the Board or its Committees or that she otherwise determines requires their attention.

cvshealthannualmeeting.com 19


Table of Contents

Corporate Governance and Related Matters: Board Structure and Processes

Code of Conduct

CVS Health has adopted a Code of Conduct that applies to all of our directors, officers and employees, including our CEO, CFO and Chief Accounting Officer. Our Code of Conduct is available on our website at http://investors.cvshealth.com and will be provided to stockholders without charge upon request to our Corporate Secretary. We intend to post amendments to or waivers from our Code of Conduct (to the extent applicable to our executive officers or directors) at that location on our website within the timeframe required by SEC rules.

Related Person Transaction Policy

In accordance with SEC rules, the Board has adopted a written Related Person Transaction Policy. The Audit Committee has been designated as the Committee responsible for reviewing, approving or ratifying any related person transactions under the Policy. The Audit Committee reviews the Policy on an annual basis and will amend the Policy as it deems appropriate.

Pursuant to the Policy, all executive officers, directors and director nominees are required to notify our General Counsel or Corporate Secretary of any financial transaction, arrangement or relationship, or series of similar transactions, arrangements or relationships, involving the Company in which an executive officer, director, director nominee, five percent beneficial owner or any immediate family member of such a person has a direct or indirect material interest.

The General Counsel or the Corporate Secretary presents any reported new related person transactions, and proposed transactions involving related persons that might be deemed to be related person transactions, to the Audit Committee at its next regular meeting, or earlier if appropriate. The General Counsel or Corporate Secretary provides the Audit Committee with an analysis and recommendation regarding each reported transaction. The Committee reviews these transactions, including the analysis and recommendation. The Audit Committee may conclude, upon review of all relevant information, that the transaction does not constitute a related person transaction, and thus that no further review is required under the Policy. If after its review, the Audit Committee determines not to approve or ratify a related person transaction, the transaction will not be entered into or continued, as the Audit Committee shall direct. The Audit Committee may ratify or approve a related person transaction if, upon consideration of all relevant information, the transaction is in, or not inconsistent with, the best interests of the Company and its stockholders.

The Audit Committee reviewed certain transactions reported under the Policy and determined that no transactions constituted reportable related person transactions under the Policy.

Corporate Governance Guidelines

The Board has adopted Corporate Governance Guidelines, which are available on our investor relations website at http://investors.cvshealth.com/corporate-governance/documents and are also available to stockholders at no charge upon request to our Corporate Secretary. These Guidelines meet the listing standards adopted by the NYSE, on which our common stock is listed.

Board Structure and Processes

The Board’s Leadership Structure

David W. Dorman is our independent Chair of the Board. The independent Chair presides at all meetings of the Board, and works with our CEO to set Board meeting agendas and the schedule of Board meetings. In addition, the independent Chair has the following duties and responsibilities:

the authority to call, and to lead, independent director sessions;
  

the ability to retain independent legal, accounting or other advisors in connection with these sessions;
 

the responsibility to facilitate communication and serve as a liaison between the CEO and the other independent directors; and
  

the duty to advise the CEO of the informational needs of the Board.

The Board believes that Board independence and oversight of management will be maintained effectively through the independent Chair, the Board’s composition and its Committee system.

20 2018 Proxy Statement


Table of Contents

Corporate Governance and Related Matters: Committees of the Board

Committees of the Board

In 2017, the Board utilized five standing committees. The table below provides membership and meeting information for each of the committees during 2017. For further details regarding current committee membership and activities see pages 22-27.

Name       Audit
Committee
      Management
Planning and
Development
Committee
      Nominating
and Corporate
Governance
Committee
      Patient
Safety and
Clinical Quality
Committee
      Executive
Committee
Richard M. Bracken C  †
C. David Brown II C   
Alecia A. DeCoudreaux   
Nancy-Ann M. DeParle   
David W. Dorman C   
Anne M. Finucane
Larry J. Merlo   
Jean-Pierre Millon  *
Mary L. Schapiro  *
Richard J. Swift C *   
William C. Weldon
Tony L. White
2017 Meetings 9   6 4 4 0  

C Committee Chair
* Audit Committee Financial Expert
Mr. Bracken joined the Executive Committee in January 2018

cvshealthannualmeeting.com 21


Table of Contents

Corporate Governance and Related Matters: Committees of the Board

Audit Committee
Each member of the Audit Committee is financially literate and independent of the Company and management under the standards set forth in applicable SEC rules and the Corporate Governance Rules of the NYSE. The Board designated each of Messrs. Swift and Millon and Ms. Schapiro as an audit committee financial expert, as defined under applicable SEC rules. The Board has approved a charter for the Committee, which can be viewed on our website at http://investors.cvshealth.com and also is available to stockholders without charge upon request to our Corporate Secretary.      

Current Committee Members
(independent)

1  Mary Schapiro*
2  Alecia DeCoudreaux
3  Richard Swift (Chair)*
4  Nancy-Ann DeParle
5  Jean-Pierre Millon*

* Audit Committee Financial Expert

Meetings in 2017: 9

Primary Responsibilities

Pursuant to its charter, the Committee assists the Board in its oversight of:

the integrity of our financial statements;
  

the qualifications, independence and performance of our independent registered public accounting firm, for whose appointment the Committee bears principal responsibility;
 

the performance of our internal audit function;
 

our policies and practices with respect to risk assessment and risk management, including discussing with management the Company’s major financial and cybersecurity risk exposures and the steps that have been taken to monitor and control such exposures;
  

compliance with, and approval of, our Code of Conduct;
 

the review of our information governance framework, including its privacy and information security programs, as well as the cybersecurity aspects of the information security program;
 

the review of our business continuity and disaster recovery program;
 

the review of our environmental, health and safety program;
 

the review and ratification of any related person transactions in accordance with our policy on such matters; and
 

our compliance with legal and regulatory requirements, including the review and oversight of matters related to compliance with Federal health care program requirements.

Audit Committee Activities in 2017

The Audit Committee met nine times in 2017 and each member of the Committee attended all of its meetings while he or she was a member. Four of the Committee’s meetings were focused primarily on our quarterly financial reports, including our Form 10-K, Forms 10-Q and our related earnings releases. At each of these meetings the Committee reviewed the documents in depth with our CFO and our Chief Accounting Officer, as well as our Chief Compliance Officer (CCO), Chief Audit Executive, General Counsel and other key members of management. The Committee also received reports from our internal audit department and our independent outside audit firm, Ernst & Young. The Committee regularly meets with Ernst & Young outside the presence of management, and also meets individually with members of management, including the CCO, the chief compliance officer for Omnicare and the Chief Audit Executive. In addition to its responsibilities related to our financial statements, the Committee plays a primary role in risk oversight, including reviews of our enterprise risk management program, cybersecurity efforts, business continuity and disaster recovery program, privacy programs, and environmental, health and safety program. The Committee also reviews our legal and regulatory compliance program on a quarterly basis, including oversight of the Company’s compliance with its Corporate Integrity Agreements, or CIAs. During 2017, the Committee provided the required annual certification of compliance with the Company’s 2014 CIA related to PBM operations, and also provided oversight of the 2016 CIA related to CVS Health’s institutional pharmacy services (long-term care) operations. The Committee provided the report found on page 29 of this proxy statement, recommending the inclusion of the Company’s audited financial statements in its Form 10-K.

22 2018 Proxy Statement


Table of Contents

Corporate Governance and Related Matters: Committees of the Board

Nominating and Corporate Governance Committee
Each member of the Nominating and Corporate Governance Committee is independent of the Company and management under the standards set forth in the Corporate Governance Rules of the NYSE. The Board has approved a charter for the Committee, which can be viewed on our website at http://investors.cvshealth.com and also is available to stockholders without charge upon request to our Corporate Secretary.      

Current Committee Members
(independent)

1  William Weldon
2  Anne Finucane
3  David Dorman (Chair)
4  Richard Bracken
5  David Brown

Meetings in 2017: 4

Primary Responsibilities

Pursuant to its charter, the Committee has responsibility for:

identifying individuals qualified to become Board members consistent with criteria approved by the Board;
  

recommending to the Board director nominees for election at the next annual or special meeting of stockholders at which directors are to be elected or to fill any vacancies or newly-created directorships that may occur between such meetings;
 

recommending directors for appointment to Board Committees;
 

making recommendations to the Board as to determinations of director independence;
 

evaluating Board and Committee performance;
 

considering matters of corporate governance and reviewing, at least annually, our Corporate Governance Guidelines and overseeing compliance with such Guidelines; and
 

reviewing and considering our policies and practices on issues relating to corporate social responsibility, charitable contributions, political spending practices and other significant public policy issues.

Nominating and Corporate Governance Committee Activities in 2017

The Nominating and Corporate Governance Committee met four times in 2017 and, except for one absence for one member of the Committee due to an unavoidable conflict, each member of the Committee attended all of its meetings. Throughout the year the Committee evaluated – and continues to evaluate – potential candidates for future election to the Board. In addition, the Committee reviewed the Company’s political activities and expenditures in depth during two of its meetings, and reviewed the Company’s corporate social responsibility roadmap, Prescription for a Better World, as well as the corporate social responsibility report itself. The Committee oversaw a review of all of the Company’s principal governance documents in 2017, including its Certificate of Incorporation, By-laws, Corporate Governance Guidelines, and all Committee Charters, and recommended changes to each to simplify and harmonize the documents, as well as to adopt certain leading practices. The Committee also oversaw the evaluation process for the Board and its Committees in 2017, which consisted of an in-depth interview of each director by the Company’s General Counsel. At the completion of the interview process, the General Counsel reviewed the results with the Committee and the Board, and a number of enhancements to the Board and Committee meeting process resulted. In addition, the Committee received updates regarding legal and regulatory developments related to corporate governance, as well as updates on the proxy season and stockholder communications.

cvshealthannualmeeting.com 23


Table of Contents

Corporate Governance and Related Matters: Committees of the Board

Management Planning and Development Committee      

Each member of the Management Planning and Development Committee is independent of the Company and management under the standards set forth in applicable SEC rules and the Corporate Governance Rules of the NYSE. No Committee member participates in any of our employee compensation programs and none is a current or former officer or employee of CVS Health or its subsidiaries. At its meetings, non-members, such as the CEO, the CFO, the Chief Accounting Officer; the Chief Human Resources Officer, the General Counsel, other senior human resources and legal officers, or external consultants, may be invited to provide information, respond to questions and provide general staff support. However, no CVS Health executive officer is permitted to be present during any discussion of his or her compensation or performance, and the Committee regularly exercises its prerogative to meet in executive session without management.

The Committee’s responsibilities are specified in its charter. The charter, as approved by the Board, may be viewed on our website at http://investors.cvshealth.com and also is available to stockholders without charge upon request to our Corporate Secretary.

     

Current Committee Members
(independent)

1  William Weldon
2  Tony White
3  David Brown (Chair)
4  Anne Finucane
5  David Dorman

Meetings in 2017: 6

Primary Responsibilities

Pursuant to its charter, the Committee:

oversees our compensation and benefits policies and programs generally;
  

evaluates the performance of designated senior executives, including the CEO;
 

in consultation with our other independent directors, oversees and sets compensation for the CEO;
 

oversees and sets compensation for our designated senior executives;
 

reviews and recommends to the Board compensation (including cash and equity-based compensation) for our non-employee directors; and
  

prepares and recommends to the full Board the inclusion of the Report of the Compensation Committee that is found on page 33 of this proxy statement.

The Committee may delegate its authority relating to employees other than executive officers and directors as it deems appropriate and may also delegate its authority relating to ministerial matters.

Management Planning and Development Committee Activities in 2017

The Management Planning and Development Committee met six times in 2017 and, except for one absence due to an unavoidable conflict, each member of the Committee attended all of its meetings. In addition to reviewing the independence of its advisor as described below, the Committee devoted substantial time to its oversight of the Company’s compensation and benefit programs as part of its annual governance process. This review is aimed at ensuring that the Company is providing its employees with compensation and benefit programs that are appropriate. The Committee received updates on compensation trends and legislative and regulatory developments. The Committee also reviewed the Company’s compensation programs, retirement, health and welfare plans applicable to all full-time employees. In addition, the Committee devoted considerable time to CVS Health’s stockholder outreach efforts and the feedback received from investors. The Committee’s review of executive compensation matters and its decisions, including changes made in response to input from our stockholders, is discussed in the Compensation Discussion and Analysis beginning on page 34 of this proxy statement.

24 2018 Proxy Statement


Table of Contents

Corporate Governance and Related Matters: Committees of the Board

Compensation Risk Assessment

The Committee is responsible for reviewing and assessing potential risk arising from the Company’s compensation policies and practices. In 2017, the Company performed a comprehensive risk assessment of its compensation policies and practices to ascertain any potential material risks that may be created by the programs. Included in its assessment were all major components of the Company’s compensation programs, including: the mix between annual and long-term compensation; short-term incentive program design; long-term incentive program performance measures; incentive plan performance criteria and corresponding objectives; a comparison of the Company’s programs with those of its peer group; the Company’s severance and change-incontrol policies; its recoupment policy; its share retention requirements and ownership guidelines; and the Internal Audit Department’s review of the controls regarding the Company’s long-term incentive program. The Committee considered the findings of the assessment and concluded that the Company’s compensation programs are aligned with the interests of its stockholders, appropriately reward pay for performance, and do not promote excessive risk-taking.

Independent Consultant

Exequity LLP is the Committee’s independent compensation consultant. Exequity provides no other services to the Company. Exequity’s fees for executive compensation consulting to the Committee for 2017 were $246,154. During 2017, Exequity:

Collected, organized and presented quantitative competitive market data for a relevant competitive peer group with respect to executive officers’ target, annual and long-term compensation levels;
 
Developed and delivered an annual Committee briefing on legislative and regulatory developments and trends in executive compensation and their implications for CVS Health;
 
Provided guidance, including relevant competitive market data, in support of discussions related to the design of our 2018 long-term incentive program; and
 
Analyzed market data and provided recommendations for non-employee director compensation to the Committee for approval by the Board.

The Committee believes that the advice it receives from Exequity is objective and not influenced by any other business relationship. The Committee and Exequity have policies and procedures in place to preserve the objectivity and integrity of the executive compensation consulting advice, including:

The Committee has the sole authority to retain and terminate the executive compensation consultant;
 
The consultant reports to the Committee Chair and has direct access to the Committee without management involvement;
 
While it is necessary for the consultant to interact with management to gather information, the Committee determines if and how the consultant’s advice can be shared with management; and
 
The Committee regularly meets with the consultant in executive session, without management present, to discuss recommendations.

The Committee conducts an annual review of the independence of its compensation consultant, taking into account the standards above, the items required to be considered under the NYSE listing standards and applicable rules and regulations. The Committee determined that its compensation consultant is independent and that its consultant’s work does not raise any conflicts.

cvshealthannualmeeting.com 25


Table of Contents

Corporate Governance and Related Matters: Committees of the Board

Patient Safety and Clinical Quality Committee

Each member of the Patient Safety and Clinical Quality Committee is independent of the Company and management under the standards set forth in applicable SEC rules and the Corporate Governance Rules of the NYSE. The Board has approved a charter for the Committee, which can be viewed on our website at http://investors.cvshealth.com and also is available to stockholders without charge upon request to our Corporate Secretary.

In light of the Company’s expanded offerings throughout the spectrum of health care, this Committee was formed in March 2016. Its focus is on oversight of the Company’s medical- and pharmacy-related strategies and initiatives, matters relating to the advancement of quality of pharmacy and medical care, patient safety and patient experience, and the enhancement of access to cost-effective quality health care.

     

 

2017 Committee Members
(all independent)

1  Tony White
2  Alecia DeCoudreaux
3  Richard Bracken (Chair)
4  Nancy-Ann DeParle
5  Jean-Pierre Million
 

Meetings in 2017: 4

   

Primary Responsibilities

Pursuant to its charter, the Committee:

reviews significant medical and pharmacy related strategies and initiatives of the Company, and matters concerning efforts to (1) advance the quality of pharmacy and medical care, patient safety and experience, and (2) enhance access to cost-effective quality health care;

 

reviews matters and receives reports concerning the quality performance of the Company’s (1) pharmacy and medical care, such as (a) dispensing, compounding, and infusion services and (b) nursing and medical clinic operations; (2) patient safety and experience; (3) the management of health care claims against the enterprise; and (4) regulatory activity related to pharmacy and health care;

 

takes such other actions and performs such services as may be referred to it from time to time by the Board, including the conduct of special reviews as it may deem necessary or appropriate to fulfill its responsibilities.

Patient Safety and Clinical Quality Committee Activities in 2017

The Patient Safety and Clinical Quality Committee met four times in 2017 and each member of the Committee attended all of its meetings. The Committee’s meetings focused on a wide variety of matters related to the Company’s provision of health care services across the enterprise, including retail, mail, specialty, specialty mail and long-term care pharmacy, retail clinic services provided by MinuteClinic, and drug compounding and infusion activities conducted by Coram and across the enterprise. The Committee received reports regarding regulatory activity by boards of pharmacy and nursing related to the Company. The Committee reviewed various issues related to patient safety, such as the Company’s efforts to address the opioid crisis. The Committee received updates on health care-related claims against the Company, as well as steps being taken to minimize and mitigate those claims. The Committee also provided oversight in the development and enhancement of a number of scorecards in various lines of business, and other efforts to measure and improve patient safety and clinical effectiveness.

26 2018 Proxy Statement


Table of Contents

Corporate Governance and Related Matters: Board Meetings and Attendance

Executive Committee

At all times when the Board is not in session, the Executive Committee may exercise most of the powers of the Board, as permitted by applicable law.

The Executive Committee did not meet during 2017.

Mr. Bracken, Chair of the Patient Safety and Clinical Quality Committee, was added to the Executive Committee in January 2018.

     

2017/18 Committee Members

1  Richard Bracken
2  Larry Merlo
3  David Dorman
4  David Brown
5  Richard Swift

Meetings in 2017: None


Board Meetings and Attendance

During 2017, there were twelve meetings of the Board. Directors are expected to make every effort to attend the Annual Meeting, all Board meetings and the meetings of the Committees on which they serve. All of our directors at the time of our 2017 Annual Meeting of Stockholders attended that Annual Meeting. In 2017, all directors attended more than 75% of the meetings of the Board and the Committees of which he or she was a member, with attendance averaging over 97%.

One Board meeting was our annual meeting of independent directors. The independent directors also regularly hold executive sessions during regularly scheduled Board meetings in which our management does not participate.

Non-Employee Director Compensation

CVS Health’s approach to compensating non-employee directors for Board service is to provide directors with an annual retainer comprised of a mandatory 75% paid in shares of our common stock and 25% paid in cash (or up to 100% stock at the director’s election). The payment of a significant portion of the annual retainer, and additional retainers as outlined below, in our common stock is consistent with our policy of using equity compensation to better align directors’ interests with stockholders. This also enhances the directors’ ability to meet and continue to comply with our stock ownership guidelines described below.

For the 2017-2018 Board year, the total annual retainer for non-employee directors remained $280,000, consisting of shares of our stock valued at $210,000 (the mandatory annual stock retainer) and a cash payment of $70,000 (unless the director elected to receive up to 100% of the annual retainer in shares of our common stock).

Additional retainers were paid to the Chairs of the Committees and the Board as follows: Nominating and Corporate Governance, $15,000; Patient Safety and Clinical Quality, $15,000; Management Planning and Development, $20,000; Audit, $25,000; and Independent Chairman of the Board, $275,000.

At least 75% of each additional retainer must be paid in shares of our common stock, with the remaining 25% paid in cash, unless the director elects to be paid an additional percentage in shares. Each retainer was paid in two equal installments, in May and November of 2017. Directors may elect to defer receipt of shares; deferred shares are credited with dividend equivalents to the extent dividends are paid to stockholders. There are no meeting fees.

cvshealthannualmeeting.com 27


Table of Contents

Corporate Governance and Related Matters: Non-Employee Director Compensation

Non-Employee Director Retainer Mix

All Other Compensation and Benefits

Directors are eligible to participate in the employee discount program and are subject to the same terms of the program as our employees. Directors are generally reimbursed for business expenses incurred directly in connection with their roles and duties on the Board, such as services provided by an executive assistant, travel, meals and lodging. We allow all directors to enroll themselves and their eligible dependents in our prescription drug benefit program, paying the same premium rates as employees. If a director retires from the Board with at least five years of service, we will allow continued participation in the prescription drug benefit plan for life, but the director must bear the full cost of the premium after retirement.

The following table shows amounts paid to each of our non-employee directors in 2017.

Non-Employee Director Compensation – 2017


Name        Fees Earned
and Paid
in Cash 1
($)
       Cash Fees
Elected to be
Paid in Stock 2
($)
       Stock
Awards 2
($)
       All Other
Compensation 3
($)
       Total
($)
Richard M. Bracken 70,190 3,560 221,250 510 295,510
C. David Brown II 75,000 225,000 1,962 301,962
Alecia A. DeCoudreaux 70,000 210,000 788 280,788
Nancy-Ann M. DeParle 70,087 209,913 280,000
David W. Dorman 163 142,459 427,378 570,000
Anne M. Finucane 70,000 210,000 280,000
Jean-Pierre Millon 70,087 209,913 1,962 281,962
Mary L. Schapiro 70,000 210,000 280,000
Richard J. Swift 76,250 228,750 1,962 306,962
William C. Weldon 70,000 210,000 280,000
Tony L. White 70,087 209,913 1,962 281,962
1

The amounts shown include cash payments made in lieu of fractional shares to Ms. DeParle and Messrs. Bracken, Dorman, Millon and White.

2

These awards are fully vested at grant and the amounts shown represent both the fair market value and the full fair value at grant. During 2017, each director received 2,819 shares of stock with a total value of approximately $210,000 (the mandatory annual stock retainer) on the date of grant; each director electing to receive the remaining annual retainer in stock also received 939 shares valued at $70,000 on the date of grant. Two directors also elected to receive their additional chair retainers in stock in lieu of cash. As of December 31, 2017, our directors had deferred receipt of shares of common stock as follows: Mr. Brown, 53,262; Ms. DeCoudreaux, 10,363; Ms. DeParle, 3,370; Mr. Dorman, 16,560; Ms. Finucane, 5,586; Mr. Swift, 57,420, and Mr. Weldon, 17,031.

3

Represents Company contributions for director health and prescription benefits.


28 2018 Proxy Statement


Table of Contents

Audit Committee Matters

Item 2: Ratification of Appointment of Independent Registered Public Accounting Firm

The Audit Committee of the Company’s Board of Directors has appointed Ernst & Young LLP, an independent registered public accounting firm, to audit the financial statements of the Company for the fiscal year ending December 31, 2018, and recommended to our full Board that it approve that appointment. We are submitting the appointment by the Committee to you for your ratification.

                   
   

The Board of Directors unanimously recommends a vote ✓ FOR  this proposal.

Audit Committee Report

During 2017, the Committee was composed of either four or five independent directors, with Ms. Schapiro joining the Committee after her election to the Board in May 2017. Set forth below is the report of the Committee on its activities with respect to CVS Health’s audited financial statements for the fiscal year ended December 31, 2017 (audited financial statements).

The Committee has reviewed and discussed the audited financial statements with management;
 
The Committee has discussed with Ernst & Young, CVS Health’s independent registered public accounting firm, the matters required to be discussed under applicable auditing standards;
 
The Committee has received the written disclosures and the letter from Ernst & Young pursuant to applicable requirements of the Public Company Accounting Oversight Board regarding Ernst & Young’s communications with the Committee concerning independence, and has discussed with Ernst & Young its independence from the Company; and
 

Based on the review and discussions referred to above and relying thereon, the Committee recommended to the Board of Directors that the audited financial statements be included in CVS Health’s Annual Report on Form 10-K for the fiscal year ended December 31, 2017, for filing with the SEC.


Richard J. Swift, Chair Alecia A. DeCoudreaux Nancy-Ann M. DeParle Jean-Pierre Millon Mary L. Schapiro

Independent Accounting Firm Independence and Fee Approval Policy

The Committee is directly responsible for the appointment, compensation, retention and oversight of the independent registered public accounting firm. The Committee has retained Ernst & Young as CVS Health’s external audit firm since September 2007. In order to assure continuing external auditor independence, the Committee periodically considers whether there should be a rotation of the audit firm. Further, in conjunction with the mandated rotation of the external audit firm’s lead engagement partner, the Committee and its chair are directly involved in the selection of Ernst & Young’s new lead engagement partner. Based on its most recent evaluation of Ernst & Young, the members of the Committee believe that the continued retention of Ernst & Young to serve as the Company’s independent registered public accounting firm is in the best interests of the Company and its stockholders. Among the factors considered by the Committee in reaching this recommendation are the following: the quality of Ernst & Young’s staff, work and quality control; its capability and technical expertise, given the complexity of the Company’s business; its independence from the Company; the quality and candor of its communications with the Company and the Committee; and the benefits of its tenure as auditors, including enhanced audit quality and competitive fees.

All audit services, audit-related services and tax services were pre-approved by the Committee, and the Committee is ultimately responsible for audit fee negotiations associated with the retention of Ernst & Young. The Committee has considered whether Ernst & Young’s provision of services is compatible with

cvshealthannualmeeting.com 29


Table of Contents

Audit Committee Matters: Item 2

maintaining Ernst & Young’s independence. The Committee’s audit approval policy provides for pre-approval of audit, audit-related and tax services that are specifically described on an annual basis to the Committee and, in addition, individual engagements anticipated to exceed pre-established thresholds must be separately approved. The policy also requires specific approval by the Committee if total fees for audit-related and tax services would exceed total fees for audit services in any fiscal year. The policy authorizes the Committee to delegate to one or more of its members pre-approval authority with respect to permitted services, so long as such pre-approvals are reported to the full Committee at its next scheduled meeting.

Representatives of Ernst & Young will be at the Annual Meeting to answer your questions and will have the opportunity to make a statement if they so desire.

If you do not ratify the appointment of Ernst & Young, the Committee will reconsider its appointment, although in the event of reconsideration the Committee may determine that Ernst & Young should continue in its role. Even if you do ratify the appointment, the Committee retains its discretion to reconsider its appointment if it believes that reconsideration is necessary in the best interest of the Company and the stockholders.

Fees of Independent Accounting Firm

The following table summarizes the fees paid to Ernst & Young for services rendered during fiscal 2017 and 2016.

           Fiscal Year
Ended
12/31/17
           Fiscal Year
Ended
12/31/16
Audit Fees 1 $10,530,000 $10,360,000
Audit Related Fees 2 $1,318,736 $624,008
Tax Fees 3 $1,420,837 $2,985,026
All Other Fees
1 Represents the aggregate fees and expenses billed for the audit of our consolidated financial statements and the audit of our internal control over financial reporting for the fiscal year, the reviews of the condensed consolidated financial statements included in our Quarterly Reports on Form 10-Q, audits of our insurance captives, services provided in connection with statutory and regulatory filings for the fiscal year, and consultations on technical matters.
2 Represents the aggregate fees billed for audit and other services that are typically performed by auditors, including audits of our employee benefit plans, compliance reporting, non-financial metric reporting and certain agreed upon procedures.
3 Includes $170,000 and $272,450 for the years ended December 31, 2017 and 2016, respectively, related to tax compliance and preparation services.

30 2018 Proxy Statement


Table of Contents

   

Executive Compensation and Related Matters

Item 3: Say on Pay, a Proposal to Approve, on An Advisory Basis, the Company’s Executive Compensation

Background

We are asking our stockholders to approve, on an advisory basis, the compensation paid to our named executive officers, as described in the Compensation Discussion and Analysis (CD&A) and the Executive Compensation section of this proxy statement. Although the advisory vote is not binding upon the Company, the Management Planning and Development Committee (referred to in this Item 3 as the Committee), which is responsible for designing and administering our executive compensation program, values our stockholders’ opinions and will continue to consider the outcome of the vote in its ongoing evaluation of our executive compensation program.

At CVS Health, our executive compensation philosophy and practice reflect our unwavering commitment to paying for performance – both short- and long-term. We define performance as the achievement of results against challenging internal financial targets that take into account our results relative to that of our peer companies, as well as industry and market conditions. We believe that our multi-faceted executive compensation plans, with their integrated focus on short- and long-term metrics, provide an effective framework by which progress against our strategic goals may be appropriately measured and rewarded.

Our 2017 Vote; Stockholder Outreach

Following our 2017 Annual Meeting of Stockholders, the Committee reviewed the results of the stockholder advisory vote on executive compensation that was held at the meeting with respect to the 2016 compensation actions and decisions for the named executive officers. Approximately 61% of votes were cast in favor of the proposal; this was lower than the support received in 2016 (80% in favor). During the fall of 2017 and early winter of 2018, we contacted our 50 largest stockholders, holders of more than 50% of our common stock, to get their views on our program. We conducted meetings with investors holding nearly 25% of our common stock and both of the leading proxy advisory firms. Committee Chair David Brown and Board Chair (and Committee Member) David Dorman participated directly in a number of these meetings. Given the lower level of support in 2017, it was clear that our stockholders were not fully supportive of all aspects of our pay program. After careful consideration of stockholder feedback, the Committee implemented several changes to our plan design aimed principally at enhancing the performance-based nature of the program and increasing overall transparency, including:

denominating long-term incentive plan awards in stock, i.e., performance share units, or PSUs, rather than denominating them in cash and settling them in stock, which simplifies the reporting of the awards and further aligns the program to our stockholders;

enhancing the performance mix of long-term incentives, by replacing time-based restricted stock units with PSUs, and implementing a two-year post-vest holding period for shares delivered under PSUs; and

revising the comparator group for measuring relative total shareholder return (TSR) under our Long-Term Incentive Plan (LTIP) from the full S&P 500 to an index of approximately 100 companies that more closely reflects our business.

We are also enhancing the disclosure and providing more insight into the Committee’s evaluation of each executive’s individual goals and performance under the annual incentive plan.

Our 2017 Performance and Pay Actions

In 2017, while the Company’s performance generally was in line with our expectations, growth was less robust than levels to which we have been accustomed. Expectations for 2017 were lower than in recent years, driven primarily by the loss of retail pharmacy prescriptions associated with pharmacy network changes. As a result, net revenues grew just 4% and adjusted earnings per share increased by 1%. We returned more than $6 billion to stockholders through dividends and share buybacks, but suspended both dividend increases and the buyback program in the second half of 2017, in connection with our planned acquisition of Aetna.

The value of our named executive officers’ compensation is significantly influenced by the value of our stock. Approximately 70% of target total compensation is provided through stock-based pay (stock options, stock units and the performance-based LTIP). As a result of our long vesting periods and the two-year holding requirement for net shares issued under the LTIP, the members of our executive team, like our stockholders, have been affected by the decrease in stock price and only ultimately achieve the full value of their equity compensation by creating long-term stockholder value.

cvshealthannualmeeting.com 31


Table of Contents

Executive Compensation and Related Matters: Item 3

Conclusion; Resolution

We urge stockholders to read the letter from the Committee found on page 33 and the CD&A beginning on page 34 of this proxy statement, which describes in more detail how our executive compensation policies and procedures operate and are designed to achieve our compensation objectives, as well as the Summary Compensation Table and other related compensation tables and narratives appearing on pages 54 through 63, which provide detailed information on the compensation of our named executive officers. The Committee and the Board of Directors believe that the policies and procedures articulated in the CD&A are effective in achieving our goals and that the compensation of our named executive officers reported in this proxy statement has contributed to CVS Health’s long-term success.

Stockholders are being asked to vote on the following resolution:

“RESOLVED, that the stockholders approve, on an advisory basis, the compensation of the CVS Health executive officers named in the Summary Compensation Table, as disclosed pursuant to the SEC’s compensation disclosure rules (which disclosure includes the Compensation Discussion and Analysis, the compensation tables and other narrative executive compensation disclosures).”

                   
   

The Board of Directors unanimously recommends a vote ✓ FOR  this proposal.

32 2018 Proxy Statement


Table of Contents

   

Dear CVS Health Corporation Stockholder,

As the members of the Board’s Management Planning and Development Committee (the “Committee”), we are responsible for and highly focused on overseeing the design and implementation of competitive compensation programs that align to the interests of stockholders and demonstrate strong pay-for-performance.

Though the Company made progress on its four-point plan to return to healthy growth, the performance of our stock price was negatively impacted by headwinds that affected not just CVS Health but our industry as a whole. The industry headwinds include the possible entrance of a large retail company into the pharmacy space looking to create disruption, as well as the debate surrounding drug pricing with the potential for legislative change. Headwinds unique to CVS Health include the risks regarding the pending acquisition of Aetna, both regulatory and operational, as well as changes in the Company’s capital allocation strategy due to the acquisition. All of these factors and the result of our say on pay vote were taken into consideration as we implemented this year’s compensation program.

Last year, our say-on-pay proposal received 61% support, a clear signal by our stockholders that they were not fully supportive of all aspects of our pay program. Following the vote, the Committee conducted a thorough review of the compensation program. Committed to demonstrating responsiveness and in an effort to effectively modify the program, the Committee identified a number of potential changes it believed stockholders would find favorable, while continuing to support our compensation key principles, and embarked on a significant engagement outreach effort to seek stockholder feedback prior to implementing.

Our Committee Chair, David Brown, as well as our Independent Board Chair and Committee member David Dorman, played a meaningful role in conversations with stockholders, assisted by our legal, human resources and investor relations staff. The scope of our engagement and details on the feedback we received are outlined in the CD&A that follows. The Committee spent time discussing this feedback, which it found to be substantive and thoughtful. In response, the Committee made a number of changes in an effort to simplify, enhance the performance-based nature of the program and increase overall transparency.

The most substantive changes involve our long-term pay mix and annual incentive plan construct, where we received the most feedback. These changes are summarized below, and a comprehensive list of all changes can be found on page 44 of our CD&A.

Denominate Long-Term Incentive Plan in Stock – Beginning with the 2018-2020 performance cycle, LTIP awards will be granted as performance share units (PSUs) rather than denominated in cash and settled in stock, which simplifies the reporting and further aligns the program to our stockholders
Enhance Performance Mix of Long-Term Incentives – We are replacing time-based RSUs with PSUs; beginning with 2018 grants, PSUs will represent 75% of our CEO’s target annual long-term award (which include the LTIP described above) and will be subject to a two-year holding period

Improve Annual Incentive Plan Design – Our annual bonus will continue to be subject to the achievement of pre-established financial and non-financial metrics; the Committee will also enhance its disclosure and provide greater insight into the evaluation of each executive’s individual performance and our annual bonus decisions

We are proud of the effort our Committee undertook this year and the changes made in response. We hope that stockholders see these changes as positive progress and recognition that their views and perspectives are greatly valued. We believe that our compensation programs drive the right behaviors for our executives, which in turn benefits our stockholders by driving our business strategies and goals. We look forward to ongoing dialogue with our stockholders and to continuing to work collaboratively.

David W. Dorman Tony L. White C. David Brown II
(Chair)
Anne M. Finucane William C. Weldon

Report of the Compensation Committee

We met with management to review and discuss the Compensation Discussion and Analysis (CD&A). Based on that review and discussion, we recommended to the Board that the CD&A be included in this proxy statement.

cvshealthannualmeeting.com 33

Table of Contents

Report of the Compensation Committee: Compensation Discussion and Analysis

Compensation Discussion and Analysis

The CD&A explains how our executive compensation programs are designed and operate with respect to our named executive officers, who for 2017 are:

Larry J. Merlo President and Chief Executive Officer
David M. Denton EVP and Chief Financial Officer
Helena B. Foulkes Former EVP and President – CVS Pharmacy – Ms. Foulkes resigned in February 2018
Jonathan C. Roberts EVP and Chief Operating Officer
Thomas M. Moriarty EVP, Chief Policy and External Affairs Officer, and General Counsel

The CD&A is organized into the following sections:

Summary
page 34
Business and Performance Highlights
page 38
Detailed Program Discussion
page 39

Summary

Our Compensation Core Principles

Five core principles drive our executive compensation philosophy:

I.

Support, Communicate and Drive Achievement of our business strategies and goals

II.

Attract and Retain the highest-caliber executive officers by providing compensation opportunities comparable to those offered by other companies with which we compete for business and talent

III.

Motivate High Performance from executive officers in an incentive-driven culture by delivering greater rewards for superior performance and reduced awards for underperformance

IV.

Align Interest of our executive officers and our stockholders, and foster an equity ownership environment

V.

Reward Achievement of short-term results as well as long-term stockholder value creation

Management and the Committee believe these principles motivate our executive officers to take personal responsibility for the performance of the business and deliver long-term stockholder value, consistent with CVS Health’s values of Innovation, Collaboration, Caring, Integrity and Accountability.

Our compensation programs:

Are tailored to our short- and long-term business strategies and drive performance,
Reflect the rapidly changing health care landscape,
Drive sustainable performance in an era where human, social, natural, and intellectual capital are joining financial and operating capital as performance drivers, and
Operate within strong governance parameters.

Stockholder Outreach and Consideration of 2017 “Say On Pay” Vote

Following our 2017 Annual Meeting of Stockholders, the Management Planning and Development Committee reviewed the results of the stockholder advisory vote on executive compensation. Approximately 61% of votes were cast in favor of the proposal, which was a decline from 80% in 2016.

Management and the Board conducted extensive outreach with our stockholders leading up to and following our 2017 Annual Meeting to better understand their perspectives on our compensation program, particularly for those who voted against our say-on-pay proposal. In total, we reached out to stockholders representing over 50% of our outstanding shares and had conversations with holders of nearly 25% of our outstanding shares. In some instances we met with the same stockholder more than once; however, each stockholder is reflected in the engagement figures only once. A number of stockholders declined our invitation to meet, including stockholders representing 13.2% of outstanding shares that responded indicating a meeting was unnecessary. We also engaged with the two leading proxy advisory firms.

34 2018 Proxy Statement


Table of Contents

Report of the Compensation Committee: Compensation Discussion and Analysis

The Chair of the Committee, David Brown, or our Independent Board Chair, David Dorman, who is also a member of the Committee, participated in many of these meetings with stockholders and with both proxy advisory firms, and feedback received was shared and discussed with the full Board.

During our outreach, we discussed several potential changes to the compensation program that the Committee was considering following our 2017 Annual Meeting.

Enhancements to Executive Compensation Program

As a result of investor feedback, the Committee approved several changes to our compensation program in an effort to simplify, enhance the performance-based nature of the program and increase overall transparency. This follows a number of enhancements made to the program following stockholder feedback in prior years.

2018 Enhancements To Executive Compensation Program
Denominate Long-Term Incentive Plan (LTIP) in Stock      

Effective with the 2018-2020 performance cycle, all LTIP grants will be denominated as performance share units (PSUs). We historically denominated our LTIP as a cash value and at the end of the three-year performance period, applied the performance adjustment to that cash value and settled the awards partly in cash and partly in stock. Based on feedback from stockholders, beginning with the 2016-2018 cycle, we provided for the awards to be settled 100% in stock.

Even after the 2016 change, some stockholders continued to find the disclosure surrounding the LTIP confusing; many suggested a preferable and more common approach to denominate grants in shares. Thus beginning with the 2018-2020 cycle, we will grant awards in the form of PSUs that will be reported in the Summary Compensation Table in the year of grant.

Enhance Performance Component of Long-Term Incentives

Beginning with 2018 grants, we will replace time-based RSUs with PSUs (with a three-year performance period), resulting in 75% of our target annual long-term incentive grant value being performance-based. The remaining 25% are grants of stock options which some stockholders view as performance-based or performance-aligned. Shares delivered in settlement of PSUs are subject to a two-year holding period and are not eligible for dividend equivalent payments (unlike the prior unvested RSUs).

Prior to 2018, RSUs accounted for 25% of an executive’s long-term incentives, and investors indicated a preference for greater emphasis on PSUs.

Increase Portion of Long-Term Incentives Subject to Holding Period

Because PSUs are subject to a holding period, and we will now be settling LTIP awards fully in shares that are also subject to a holding period, the portion of awards subject to a holding requirement by our executives will increase.

Investors have provided positive feedback on the two-year holding requirement, recognizing that it further aligns executive and stockholder interests over a longer term.

Improve Annual Incentive Plan Design

For the 2018 performance year, we will simplify the design of the annual incentive program and eliminate the bonus pool. Named executive officers will be eligible for maximum awards based on competitive targets. The plan will continue to use rigorous goals for operating profit that align to our external financial guidance along with customer satisfaction and client service goals that the Committee believes are leading indicators of future performance. The plan also incorporates individual goals for each named executive officer.

Stockholders indicated that the annual plan was too complex.

Add Transparency for Individual Component of Annual Incentive Plan

Effective this year, we will enhance the disclosure and provide more insight into the Committee’s evaluation of each executive’s individual goals and performance under the annual incentive plan.

Stockholders indicated a preference for greater transparency.

Adjust Comparator Group For Relative TSR Performance Modifier

The comparator group for measuring relative TSR under our LTIP will change beginning with the 2018-2020 LTIP cycle from the S&P 500 to an index of companies that more closely reflects our business. Specifically, this group will include approximately 60 health care and 40 consumer staples companies.

We received feedback that a comparator group more closely aligned to our business might be more appropriate, and would help to mitigate some of the macro issues that impact the share price of a particular industry or industries.


cvshealthannualmeeting.com 35


Table of Contents

Report of the Compensation Committee: Compensation Discussion and Analysis

The above changes are in addition to enhancements made to our compensation program in prior years as a result of stockholder input that remain in effect, including:

Reducing maximum awards under the annual bonus plan,
 
Providing that dividend equivalents on RSUs are only paid out when and if awards vest, and
 
Revising the TSR modifier beginning with the 2017-2019 LTIP cycle by applying it in pro-rated quartiles that reduce payouts for performance below the 50th percentile.

Compensation Program Design

Our pay-for-performance philosophy places a majority of an executive officer’s compensation at risk and emphasizes long-term incentives tied to individual and company performance as well as continued service. As a result, the only fixed compensation paid is base salary, which represents 9 percent of the CEO’s total target compensation and no more than 15 percent of the other named executive officer’s total target compensation.

2017 CEO Target Pay Mix

2018 CEO Target Pay Mix

Impact of LTIP Plan Design Changes: Transition in PSU Settlement

In 2016, in response to stockholder feedback, the Company moved from an LTIP award that was partially settled in cash to awards denominated in cash and settled 100% in stock. This resulted in a change in our reporting as previously awards were reported half in the year of grant and half in the year of vesting. Under SEC guidance, the three-year performance cycles beginning in 2016 and 2017 are reported at the end of the cycle as cash even though they will be paid in stock. Although our stockholders generally approved of the design (payment in stock with an extra two-year holding period), they found the multi-year reporting confusing and it resulted in an incomplete analysis of our compensation program. To address this, commencing with the 2018-2020 performance period, LTIP awards will be made in Performance Stock Units reported in the year of grant and will appear as equity awards in the Summary Compensation Table.

During the transition period, which includes the payout of the 2015-2017 cycle and continues through the payment of the 2017-2019 cycle, there will be timing issues that occur as awards for multiple years will appear in the Summary Compensation Table as follows:

2017 will include the cash portion earned for the 2015-2017 cycle (the stock portion was reported for 2015)
 
2018 will include 100% of the value earned for the 2016-2018 cycle and 100% of the target award granted for the 2018-2020 cycle.
 
2019 will include 100% of the value earned for the 2017-2019 cycle and 100% of the target award granted for the 2019-2021 cycle.

We will return to normal, single-cycle reporting in 2020.

36 2018 Proxy Statement


Table of Contents

Report of the Compensation Committee: Compensation Discussion and Analysis

The table below shows the Committee’s compensation determinations for 2017 for our named executive officers. This table is different from the SEC-required 2017 Summary Compensation Table on page 54. The table includes base salary on April 1, 2017, the annual cash incentive paid in March 2018 for performance year 2017, RSUs and options granted in 2017, the 2017-2019 LTIP (which is not shown in the Summary Compensation Table per SEC reporting) and All Other Compensation for 2017.

2017 Named Executive Officer Annual Compensation Determinations

Named Executive Officer      Salary      Annual
Incentive
Award
     RSUs 1      Options      2017-2019 LTIP
Awarded
in 2017
(not included
in SCT)
     All Other
Compensation
     Total
Compensation
Larry J. Merlo $1,630,000 $2,128,800 $3,374,960 $3,374,998 $6,750,000 $754,106 $18,012,864
David M. Denton   $850,000 $833,000 $999,977 $999,977 $2,000,000 $334,979 $6,017,933
Helena B. Foulkes 2 $950,000 $0 $169,006 $1,119,006
Jonathan C. Roberts $1,050,000 $1,200,000 $1,999,953 $1,999,994 $3,750,000 $244,484 $10,244,431
Thomas M. Moriarty $750,000 $845,000 $1,249,971 $1,249,998 $1,875,000 $102,585 $6,072,554
1

With respect to RSUs awarded for 2017, the number of units awarded was determined by dividing the dollar amount shown in the table by a share price of $78.05, which was the grant date closing price.

2 Ms. Foulkes was granted a target award of $2,000,000 for the 2017-2019 LTIP and 2017 options and RSUs with a combined target value of $3,000,000, and has forfeited these awards due to her resignation.

Leading Practices In Compensation Programs

Our pay practices align with our core compensation principles and facilitate our implementation of those principles. They also demonstrate our commitment to sound compensation and governance practices.

Our executive compensation program motivates executive officers to take personal responsibility for the performance of CVS Health Core Executive Compensation Principles Designed to Promote Company Growth
Performance Measures Aligned with Stockholder Interests
Majority of the Total Compensation Opportunity is Performance-Based
LTIP Awards Settled in Common Stock that is Subject to Retention Requirement (Holding Period)
Total Shareholder Return (TSR) Modifier Provides for Reduced Payout for Below Median
Performance Stock Ownership Guidelines
We apply leading executive compensation practices No Excise Tax Gross-Ups
No Option Repricing
No Recycling of Shares
Recoupment Policy
Broad Anti-Pledging and Hedging Policies
Executive Severance Policy
Limited Perquisites and Personal Benefits
SERP Closed to New Participants
Double Trigger Vesting of Equity Awards
Dividend Equivalents on RSUs Paid Only When Awards Vest
Board Committee Oversight of Comprehensive Annual Compensation Program Risk Assessment
Reduced Maximum Annual EIP Award to Align with Broad-Based MIP
NEW THIS YEAR Replaced Cash Denominated LTIP with Performance Stock Units
Replaced Time-Based RSUs with Performance Stock Units
Increased Portion of Equity Subject to a Two-Year Holding Requirement
Simplified and Improved Disclosure for Annual Incentive Plan

cvshealthannualmeeting.com 37


Table of Contents

Report of the Compensation Committee: Business and Performance Highlights

Business and Performance Highlights

We are a pharmacy innovation company helping people on their path to better health. At the forefront of a changing health care landscape, we have an unmatched suite of capabilities and the expertise needed to drive innovations that will help shape the future of health care. Through our more than 9,800 retail locations, more than 1,100 walk-in medical clinics, a leading pharmacy benefits manager with more than 94 million plan members, a dedicated senior pharmacy care business serving more than one million patients per year, expanding specialty pharmacy services and a leading stand-alone Medicare Part D prescription drug plan, we enable people, businesses, and communities to manage health in more affordable and effective ways.

In 2017, we delivered on the four-point plan we set in place to return to more robust levels of growth. Our position in the evolving health care landscape is stronger than ever before, and we remain confident in our model and in our ability to make health care more affordable, more accessible and more effective.

                 
     
4.1%
net revenue growth
      Increased dividend to
$2.00 per share
Return of
>$6 billion
to stockholders through dividends and share repurchases
Outperformed the S&P 500 and Dow Jones Industrial Average for the prior 5 and 10 years

The rapidly changing health care landscape continues to include uncertainties concerning health care policy. The exclusion of CVS Pharmacy from certain health plan retail networks, resulting in the loss of prescription volume beginning in late 2016, created a headwind for 2017. Compensation to our executives, including the cash component, the long-term incentive plan cycle ending in 2017 and the value of our outstanding stock awards, is – and should be – affected by such factors, whether or not those factors are within management’s ability to influence.

   
      
  For more information on our financial performance and strategy, please refer to our Annual Report available at www.cvshealthannualmeeting.com. Please also refer to page 52 of this proxy statement for additional information about how we calculate Return on Net Assets, a metric used in our Long-Term Incentive Plan.  

We are committed to helping people on their path to better health. Our values of innovation, collaboration, caring, integrity and accountability affect how we drive performance. We are strongly committed to evaluating and incenting management to remain focused on drivers of sustainable performance, even though we recognize that this focus is not always reflected in the stock price. We invest in our employees at all levels in the Company by rewarding performance that balances risk and reward, is consistent with our values and supports short- and long-term goals and, ultimately, value creation for our stockholders. We provide opportunities for professional growth and development and aim to offer affordable benefits and programs that meet the diverse needs of our employees and their families. Feedback from stockholders during our annual outreach confirms strong support for this commitment and for the value we place on other forms of capital—including human, natural, social and intellectual:

We include retail customer service and PBM client satisfaction in our pay calculations.
 
Our decision to remove tobacco from pharmacy stores continues to show positive results by reinforcing the value of our brand in health care.
 
We launched a multi-front fight against the opioid epidemic through enhanced opioid utilization management practices that follow the Centers for Disease Control Guidelines, an expanded drug disposal collection program and an education program taught by our pharmacists in the schools in their communities.
 
We value the recruiting and reputation advantages of placing second in our sector of World’s Most Admired Companies, of placing seventh in Fast Money’s list of 50 Most Innovative Companies, and of being one of Forbes’ Most Admired Brands, CR Magazine’s 100 Best Corporate Citizens, Points of Light 50 most community-minded companies in the US and Newsweek’s Top 20 Greenest Companies in America.
 
We have made significant investments in our colleagues by raising the minimum starting wage enterprise-wide and offering paid family leave for all new parents, both effective April 1, 2018. We also plan to increase pay ranges and rates for many of our retail hourly employees effective July 1, 2018, and we will not increase employee health plan premiums for the 2018-2019 plan year despite a 5% increase in costs, indicative of our commitment to ensuring access to affordable health care.
 
Our holistic approach to leveraging diversity within our talent pipeline, talent development, leadership accountability and supplier diversity, earned us a spot on the DiversityInc Top 50 Companies for Diversity list.

38 2018 Proxy Statement


Table of Contents

Report of the Compensation Committee: Detailed Program Discussion

We are proud to be named to the Billion Dollar Roundtable, an organization that recognizes and supports corporations that achieve $1 billion in annual spending on diverse- and women-owned suppliers.
 
We achieved a 100% score on The Disability Equality Index, a joint initiative of the American Association of People with Disabilities and the US Business Leadership Network for our commitment to recruiting and retaining talent from the disabilities community and our utilization of disability-owned companies as part of our supplier base.
 
We achieved a perfect score for the fourth consecutive year on the 2018 Corporate Equality Index, a national benchmarking survey and report on corporate policies and practices related LGBTQ workplace equality administered by the Human Rights Campaign Foundation.

In December 2017, CVS announced that it will acquire Aetna Inc. CVS believes that Aetna will complement its competitive strategy, which is built on a diversified set of core and emerging businesses that enable it to better compete with more cost-effective products, pursue profitable growth across a range of opportunities and lead the transformation of health care. CVS stockholders approved the issuance of shares in the merger and Aetna shareholders approved the merger at special meetings held on March 13, 2018. The transaction remains subject to regulatory approvals and is expected to close in the second half of 2018.

Detailed Program Discussion

CVS Health Values

When determining compensation awards and incentive payments, the Committee validates that results were achieved in line with the Company’s five core values:

Innovation                             Collaboration                         Caring                         
 
Demonstrating openness,
curiosity and creativity in the
relentless pursuit of
delivering excellence.
Sharing and partnering with
people to explore and
create things that we could
not do on our own.
Treating people with respect
and compassion so they
feel valued and appreciated.

Integrity                               Accountability                 
 
         Delivering on our promises;
doing what we say and
what is right.
       Taking personal ownership
for our actions and
their results.

cvshealthannualmeeting.com 39


Table of Contents

Report of the Compensation Committee: Detailed Program Discussion

Executive Compensation Planning and Review Process

The following serves as the framework the Committee follows to review, discuss and approve all aspects of our executive compensation program.

               
 
 
SEPTEMBER
MP&D Committee Meeting
Annual risk assessment of compensation programs
Peer group reviewed and established for executive compensation benchmarking
Pay-for-performance alignment for prior year reviewed
           

The annual cycle of reviewing and developing the Company’s executive compensation program and pay levels is a multi-step process that incorporates input from stockholders, management, peer group information, consideration of say-on-pay results, and both short- and long-term Company results compared to objectives, as well as consultation with the Committee’s independent compensation consultant.

Throughout the annual compensation cycle, Committee decisions incorporate and reflect our deep commitment to the Company’s five core values: Innovation, Collaboration, Caring, Integrity, and Accountability.

 
 
NOVEMBER
MP&D Committee Meeting
Total compensation market data for our executives reviewed
Stockholder comments received on our executive compensation program
 
 
JANUARY
MP&D Committee Meeting
Review any additional stockholder comments received on our executive compensation program
Preliminary financial results reviewed
Preliminary incentive award payouts for the completed fiscal year

CEO Performance Review
The CEO presents a self-assessment of his performance against his Board-approved strategic, operational and financial goals
The Chairman of the Board and the Committee Chair meet with the independent directors privately to consider the CEO’s performance
Committee members consult with their independent compensation consultant and consider the independent directors’ assessments in reviewing the CEO’s total compensation and determining his annual incentive compensation award and equity compensation grants
 
 
FEBRUARY
MP&D Committee Meeting
Other Named Executive Officer Final Decisions
For named executive officers other than the CEO, final decisions on actual incentive awards for the prior year are made in February after review of the CEO’s assessment of individual executive contribution and performance; as described above, the CEO’s performance is reviewed separately
 
 
MARCH
MP&D Committee Meeting
Target Setting
The Committee establishes financial targets and approves any base salary changes and individual target incentive award levels for the current performance year
 
 

 


40 2018 Proxy Statement


Table of Contents

Report of the Compensation Committee: Detailed Program Discussion

Elements of Compensation Program

The Committee believes each element of our executive compensation program furthers one or more of our five core principles:

I. Support, Communicate and Drive Achievement       IV.  Align Interests
II. Attract and Retain V. Reward Achievement
III.  Motivate High Performance

The table below outlines each element of our compensation program on a going forward basis, its connection to our five core principles, as well as how they support our long-term strategy and growth. The table does not include RSUs as they were removed from our LTI program effective 2018.

2018 Compensation Program

         Settled in       Target Basis       Link to Strategy/
Growth
      Additional Information
Base
Salary
Cash
Set based on experience, market and responsibility
Reviewed annually
 
Adjusted periodically based on market positioning and individual qualifications
Annual
Cash
Incentive
Cash
Financial and non-financial targets approved at the beginning of the fiscal year
Key measure of profitability followed closely by investors
 
Important driver of recurring revenue and long-term strategic and operational goals
Payments reflect performance against operating profit target
 
Maximum payouts capped as percent of base salary
 
Committee evaluates financial and customer service metrics and individual performance
LTIP
Stock
Established at start of a three year cycle
 
Based on market data, level of responsibility, and desired pay mix
Measures profitability and efficient management of cash, inventory, and accounts receivable
 
Provides link to market-based outcomes
Performance threshold required for any payout
 
Maximum payouts capped
 
Denominated and settled in stock
 
2-year holding period post vesting
PSUs
 NEW  
Stock
Established at start of a three year cycle
 
Based on market data, level of responsibility, and desired pay mix
Measures profitability and cash flow
Performance threshold required for any payout
 
Maximum payouts capped
 
Denominated and settled in stock
 
2-year holding period post vesting
Stock
Options
Stock
Based on market data, level of responsibility, and desired pay mix
Stock price appreciation aligned to stockholder interests
7-year term
 
Vest annually over 4 years

cvshealthannualmeeting.com 41


Table of Contents

Report of the Compensation Committee: Detailed Program Discussion

Performance Metrics Support Corporate Strategy and Long-Term Growth

The Committee recognizes that external factors that are beyond CVS Health’s influence may impact its stock price. Consequently, the Committee believes that other performance indicators, including profitability and sound financial management of our working capital, should also be factored into our executive compensation program. By using a variety of pay vehicles and balancing short- and long-term awards, the Committee believes the program supports retention and long-term growth creation because the metrics are measured independently and no one factor impacts all elements of performance.

Pay Element         Performance Metric         Rationale
Annual Cash Incentive Operating Profit
Key measure of profitability followed closely by investors
Retail Customer Service /
PBM Client Satisfaction
Important driver of recurring revenue and long-term strategic and operational goals
Individual Performance
Goals
Drives specific, job-related performance that is linked to overall company performance
LTIP RoNA
Measures performance in a way that is easily understood by participants and valued by investors
TSR
Captures both income and balance sheet impacts, including capital management actions
Provides a useful gauge of overall performance while limiting the effects of factors management cannot influence
Correlates to creation of long-term shareholder value and free cash flow
TSR modifier measures performance relative to the broad market in which we compete for talent and capital
PSUs EBITDA
Measures profitability and cash flow

Base Salary

The Committee annually reviews the base salaries of all senior officers, including the NEOs, and adjusts them periodically as needed to maintain competitiveness and consistency with evolving responsibilities. Upon consideration of this competitive market analysis and input from its consultant, the Committee increased Mr. Roberts’ salary in connection with his promotion to COO in March 2017, and did not raise base salaries for any of the other named executive officers.

Annual Cash Incentive

Our NEOs participate in the Executive Incentive Plan (EIP), under which they are eligible for a cash-based award based on the achievement of pre-established financial and individual performance objectives. In the first quarter of each year, the Committee approves for each NEO an annual target bonus amount expressed as a percentage of the executive’s base salary in effect on April 1 of the year – 200% for Mr. Merlo, 175% for Mr. Roberts, and 150% for each of Ms. Foulkes and Messrs. Denton and Moriarty. Awards are paid out, if earned, in the first quarter of the following year.

2017 Annual Incentive

Under the EIP, a maximum pool is created to pay annual incentives to named executive officers. For 2017, for purposes of Section 162(m) of the Code, the Committee approved the potential funding of the awards based on the lesser of the Maximum Bonus or a portion of a bonus pool equal to 0.5% of Adjusted Income from Continuing Operations Attributable to CVS Health. For 2017, the pool funded at the Maximum Bonus as those amounts were less than the Adjusted Income from Continuing Operations pool.

42 2018 Proxy Statement


Table of Contents

Report of the Compensation Committee: Detailed Program Discussion

The award is granted under our stockholder-approved, long-term incentive plan at 200% of each such senior executive’s target annual bonus amount, which reflects the maximum potential award. Payment is based on the objective financial goal, which is established at the beginning of the fiscal year. For 2017, metrics included Adjusted Operating Profit and a modifier (downward only) for Customer Service / PBM Client Satisfaction. Actual payments may not exceed 20% of the funding result.

2017 Objective Financial Goals

Performance Metric       Target       Actual       Funding
Adjusted Operating Profit (MIP) $10,551 $10,193 65.3%
Customer Service / PBM Client Satisfaction 100% 95%

The Committee evaluates each named executive officer’s performance and considers Mr. Merlo’s input on the performance of the other named executive officers. For 2017, the Committee reduced the actual payout of the awards for each named executive officer. This decision was based on a variety of objective factors established at the beginning of the year and subjective factors based on a review of the year, including (i) the percentage payout under the 2017 Management Incentive Plan applicable to employees below the senior executive level, which paid out at 65.3% of target based on 2017 Adjusted Operating Profit (performance of 96.6% of target resulting in funding of 66%) as well as customer and client satisfaction that resulted in a negative adjustment of 0.7 percentage point or a final funding of 65.3% and (ii) the individual performance of each named executive officer as set forth below.

Executive         Fiscal 2017 Individual Performance Assessment

Larry J. Merlo

The Committee recognized Mr. Merlo’s leadership in architecting and structuring the planned transformative merger with Aetna, as well as his overall management of the Company during a transition year. The Committee considered progress against the four point plan designed to return the Company to healthier levels of earnings growth, talent and succession planning including the hiring of a new PBM President, and the launching of industry leading programs designed to combat the opioid epidemic.
However, in acknowledgement of the Company’s 2017 financial performance that included operating profits results that were below goal, the Committee chose to position Mr. Merlo’s annual bonus at the level of the Management Incentive Plan (65.3%), comparable to bonuses received by executives below the proxy officer level.

David M. Denton

The Committee recognized Mr. Denton’s leadership in negotiating and structuring the planned merger with Aetna, and in developing and executing the underlying financial structure to support the deal. The Committee also considered progress against the four point plan designed to return the Company to healthier levels of earnings growth.
However, in acknowledgement of the Company’s 2017 financial performance that included operating profit results that were below goal, the Committee chose to position Mr. Denton’s annual bonus at 65.3% of his competitive target, comparable to bonuses received by executives below the proxy officer level.

Jonathan C. Roberts

The Committee recognized Mr. Roberts’ successful accession to the Chief Operating Officer role and subsequent positive impact on financial and operating results in the Retail business, while continuing his leadership of the PBM business during the search for a new President.
However, in acknowledgement of the Company’s 2017 financial performance that included operating profit results that were below goal, the Committee chose to position Mr. Robert’s annual bonus at the 65.3% of his competitive target, comparable to bonuses received by executives below the proxy officer level.

Thomas M. Moriarty

The committee recognized Mr. Moriarty’s results in establishing and advancing strong policy positions to support the Company’s businesses as well as his superior management of the Government Affairs and Legal functions. In addition, Mr. Moriarty displayed strong leadership in negotiating and structuring our planned merger with Aetna.
Reflecting the Company’s 2017 financial performance that included operating profit results that were below goal, the overall funding level of the Management Incentive Plan for non-executive officers in the Company as well as his superior personal contribution, the Committee chose to establish Mr. Moriarty’s baseline bonus at 75.1% of his competitive target funding.

cvshealthannualmeeting.com 43


Table of Contents

Report of the Compensation Committee: Detailed Program Discussion

The actual payout of each award, as adjusted and approved by the Committee, is set forth in the table below. Ms. Foulkes left the Company before the payment date for the annual bonus and, as a result, did not receive a payment in respect of 2017.

2017 Annual Incentive Payments

Executive       Maximum Potential
Bonus Award
      Target Bonus as a
Percentage of Base
Salary
      Target Bonus       Actual Bonus       Actual Bonus as
a Percentage of
Target
Larry J. Merlo $6,520,000 200% $3,260,000 $2,128,800 65.3%
David M. Denton $2,550,000 150% $1,275,000 $833,000 65.3%
Helena B. Foulkes $2,850,000 150% $1,425,000 $0 0%
Jonathan C. Roberts $3,675,000 175% $1,837,500 $1,200,000 65.3%
Thomas M. Moriarty $2,250,000 150% $1,125,000 $845,000 75.1%

2018 Annual Incentive

In response to stockholder feedback, the Committee streamlined the program, retaining the key financial and operational goals to measure company performance and formalizing the evaluation of individual performance. The Committee eliminated the IRC 162(m) bonus pool concept. For 2018, annual incentives will be determined as follows:

Annual
Base Salary
X Target Annual
Incentive %
X Company
Performance %
X Individual
Performance %
= Final Award

The Committee will measure company performance using Operating Profit (80% weighting) and Customer Service and Client Satisfaction (20% weighting as a negative modifier to Operating Profit results). The Committee established challenging targets for Operating Profit that are consistent with the earnings guidance we provided to investors. Our retail customer service and client satisfaction metrics insure that we are providing excellent service and position us to retain and win new business. The Operating Profit and Customer Service and Client Satisfaction goals for 2018 were set above 2017 actual performance. The Committee also approved individual goals and objectives for business operations, merger and integration, and talent and organizational development. Those will be evaluated against performance and assigned a value between 0 and 120% to arrive at the actual payment. In all cases, payouts cannot exceed 200% of target.

Long-Term Incentive Compensation

As part of the Committee’s comprehensive review of our compensation program, which included input from our stockholders, it approved changes to the long-term incentive compensation plans (LTI plans) to enhance the performance component. Beginning with 2018 grants, we will replace time-based RSUs with PSUs with a three-year performance period for our named executive officers.

Long-Term Incentive Target Mix

2017 Long-Term Mix
 

2018 Long-Term Mix


44 2018 Proxy Statement


Table of Contents

Report of the Compensation Committee: Detailed Program Discussion

Long-Term Incentive Plan (LTIP)

Our program features formulaically determined payouts based on performance against financial goals established at the beginning of the three-year performance period, and modified by relative TSR measured over the same period. The target, threshold and maximum goals set under the LTIP align with the Company’s long-term targets communicated to investors and at a level expected to generate strong operational execution. The Committee has historically selected RoNA as the performance metric under the LTIP for a number of reasons, including:

Measures performance in a way that is easily understood by participants and valued by investors
 

Captures both income and balance sheet impacts, including capital management actions
 

Provides a useful gauge of overall performance while limiting the effects of factors management cannot influence
 

Correlates to creation of long-term shareholder value and free cash flow

The TSR modifier measures performance relative to the broad market in which we compete for talent and capital. Awards earned after the three-year performance period are subject to an additional two-year holding period.

Beginning with the 2018 LTIP grant, the comparator group for measuring relative TSR will change from the S&P 500 to an index of approximately 60 health care and 40 consumer staples companies that more closely reflect our business. The companies included in this peer group are listed at the end of this Compensation Discussion and Analysis.

As a result of feedback from our stockholders, the Committee revised the TSR modifier for the cycle beginning in 2017 such that awards are adjusted if performance is above or below the 50th percentile as shown in the chart. In addition, the modifier is applied in quartiles on a pro-rata basis to provide for reduced payout for below median performance.


Based on stockholder feedback, in 2016, we moved from an LTIP award that was partially settled in cash to awards denominated in cash and settled 100% in stock. This resulted in a change in our reporting as previously awards were reported half in the year of grant and half in the year of vesting. Under SEC guidance, the three-year performance cycles beginning in 2016 and 2017 are reported at the end of the three-year cycle as cash even though they will be paid in stock. Although our stockholders generally approved of the design (payment in stock with an extra two-year holding period), they found the multi-year reporting confusing and it resulted in an incomplete analysis of our compensation program. To address this, commencing with the 2018-2020 performance period, LTIP awards will be made in Performance Stock Units reported in the year of grant and will appear as equity awards in the Summary Compensation Table.

2015-2017 LTIP Performance Period

All of the executive officers listed in the Summary Compensation Table earned payments in 2017 for awards granted in 2015 for the 2015-2017 LTIP performance period except for Ms. Foulkes, due to her resignation. The Committee set the 2015-2017 LTIP Return on Net Assets (RoNA) goal in early 2015 to align with the Company’s long-term targets communicated to investors in 2014 and at a level expected to generate strong operational execution and asset management. The RoNA result for the three year cycle was 38.12% missing the target by 133 basis points and resulting in a payout just above threshold performance. Despite solid net asset performance, continued growth in the PBM and improved cash flow, net operating profit after tax (NOPAT) was below target primarily as a result of the network changes that were announced in 2016 that excluded CVS from some networks and this resulted in below target RoNA performance. The RoNA results were adjusted to fully eliminate the benefit of tax reform. Absent this adjustment, RoNA would have been 45.43%. Based on our relative TSR over this same period, the modifier reduced the payout level as a percent of target to 36%. This outcome highlights the strong alignment of pay to performance under our compensation program.

cvshealthannualmeeting.com 45


Table of Contents

Report of the Compensation Committee: Detailed Program Discussion

The following table sets forth threshold, target and maximum goals, the range of potential payouts as a percent of target and the actual results for the 2015-2017 performance period.

      % of RoNA
Target
      Payout Level as a
% of Target
Threshold (minimum level of performance) 96.1% 40%
Actual (38.12%) 96.6% 48%
Target (39.45%) 100.0% 100%
Maximum 106.5% 200%
TSR Modifier -25% (reflecting 11th percentile) 36%

2015 – 2017 LTIP Plan Opportunities and Actual Award Payments

Executive Name       Minimum
Award
(% of
Target)
      Threshold
Award
(% of
Target)
      Target
Award
(% of
Target)
      Maximum
Award
(% of
Target)
      Maximum
Award
After TSR
Modifier
(% of
Target)
      Actual
Total
Award
At 36%
      Actual
Cash
Portion
of Award
($)
      Actual
Stock
Portion
of Award
(# of
Shares)
Larry J. Merlo 0% 40% 100% 200% 250% $1,980,000 $990,000 14,616
David M. Denton 0% 40% 100% 200% 250% $720,000 $360,000 5,315
Helena B. Foulkes 0% 40% 100% 200% 250% $0 $0 0
Jonathan C. Roberts 0% 40% 100% 200% 250% $810,000 $405,000 5,979
Thomas M. Moriarty 0% 40% 100% 200% 250% $630,000 $315,000 4,650

2016-2018 LTIP Performance Period

The LTIP for the 2016-2018 cycle is based on RoNA, and subject to a modifier based on relative TSR (S&P 500) over the same three-year period. The goal was set by the Committee in early 2016 at a challenging level to drive performance. The goal aligns with the Company’s long-term targets communicated to investors in 2015, and was set higher than the actual results for the 2013-2015 performance cycle.

2017-2019 LTIP Performance Period

The LTIP for the 2017-2019 cycle is based on RoNA, and subject to a modifier based on relative TSR (S&P 500) over the same three-year period that varies in correlation with above and below performance at the 50th percentile. The goal was set by the Committee in early 2017 at a challenging level to drive performance and generate strong operational execution and asset management. The goal aligns with the Company’s long-term steady state targets communicated to investors in 2016, and was set higher than the actual results for the 2014-2016 performance cycle.

The following table sets out the target performance-based LTIP award. If earned, the awards below will be paid in stock in early 2020 subject to a two-year holding requirement. The awards are not guaranteed and can range from 0%-250% of target. Payouts are formulaic, though the Committee has discretion to reduce awards.

Executive Name       Target Performance-Based LTIP Award
for 2017-2019 Performance Period
Larry J. Merlo $6,750,000
David M. Denton $2,000,000
Helena B. Foulkes 1
Jonathan C. Roberts $3,750,000
Thomas M. Moriarty $1,875,000
1 Ms. Foulkes was granted a target award of $2,000,000 and forfeited that award due to her resignation.

46 2018 Proxy Statement


Table of Contents

Report of the Compensation Committee: Detailed Program Discussion

2018-2020 LTIP Performance Period

For the 2018-2020 performance cycle, the Committee established a RoNA target, subject to a TSR modifier (new peer group, see page 53). The RoNA target is higher than the actual results for the 2015-2017 cycle. However, the Committee recognized that the pending acquisition of Aetna could materially alter the results of RoNA. To align with the success of the transaction and our commitment to investors, in the event the transaction closes during the first half of the performance period, the metric will be: (i) achievement of a synergy target that is consistent with the estimates we have provided to investors, (ii) development of a robust pipeline of integrated offerings designed to deliver transformation value to clients and members, and (iii) the successful launch of such offerings by December 31, 2020. The final amount will be modified by TSR ranking against the new peer group. The Committee will continue to evaluate appropriate performance metrics for future periods based on forward looking business and strategy.

PSUs

PSUs were introduced for the first time in 2018. PSUs are earned at the end of a three-year period based on the achievement of rigorous performance goals, which are established at the beginning of the performance period, and require a two-year hold period post vest.

2018-2020 PSU Performance Period

For the 2018-2020 performance period, the Committee approved EBITDA as the performance measure for the PSUs. The target, threshold and maximum goals are aligned with the Company’s long-term targets communicated to investors and at a level expected to generate strong profitability. The Committee set alternative EBITDA targets that contemplate the acquisition of Aetna closing during the performance period. The goals for the combined company are consistent with the company’s public disclosures about the transaction.

Stock Options

Options have a term of seven years and typically vest in four equal annual installments.

RSUs

RSU grants vest in two equal installments: 50% on the third anniversary of the grant date and 50% on the fifth anniversary of the grant date. As noted, the Committee will no longer award RSUs to our named executive officers as part of the LTI program.

Our LTI continues to incent actions that drive profitability and link to market outcomes, as well as reinforce the alignment between executives and stockholder interests and four strategic objectives:

Focus on the importance of returns to stockholders and alignment with changes in stock price;
 

Promote the achievement of long-term performance goals;
 

Encourage executive retention; and
 

Promote meaningful levels of Company stock ownership by executives.

To determine the overall LTI plan opportunity, the Committee considers a variety of factors, including competitive market positioning against comparable executives of the companies in the Peer Group, potential economic value realized, timing of vesting, an executive’s individual performance during the immediately preceding year, potential future contributions, prior year award value, and retention considerations. Along with a review of Peer Group long-term incentive award practices, the Committee considers the retentive value of the unvested equity awards held by each executive officer to determine whether additional awards to secure continued employment with the Company are warranted. For named executive officers other than the CEO, the Committee also considers the CEO’s recommendations.

Equity grants are made on a predetermined date consistent with the Committee’s equity grant practices. For 2017, the grant date was April 3, the first business day of the second quarter.

2017 Stock Option and RSU Grant Decisions

The following table sets out the aggregate value of stock options and RSUs granted on April 3, 2017.

Executive Name       2017 Aggregate
Equity Award Value
Larry J. Merlo $6,750,000
David M. Denton $2,000,000
Helena B. Foulkes 1
Jonathan C. Roberts $4,000,000
Thomas M. Moriarty $2,500,000
1

Ms. Foulkes was granted an award with an aggregate value of $3,000,000 and forfeited that award due to her resignation.


cvshealthannualmeeting.com 47


Table of Contents

Report of the Compensation Committee: Detailed Program Discussion

Linking Pay to Performance

For 2017, as in previous years, the Committee reviewed an historical assessment of the relationship between CVS Health’s performance and executive pay relative to our 2017 Peer Group (as described below). The following graphs illustrate the results of the Committee’s core assessment and illustrate the relationship between:

our CEO’s realized compensation (base salary earned, incentives earned, value of RSUs that vest during the period, the value of stock options exercised during the period, and changes in the value of unvested RSUs and unexercised options held during the period); and
 

CVS Health’s performance as measured by total shareholder return (TSR) – over one-year (2016), three-year (2014 – 2016) and five-year (2012 – 2016) periods (the most recent periods for which financial and compensation data were available at the time).

In the following graphs, data points that are within the shaded area designate ideal pay-performance relationships. Data points below the shaded area identify peer companies where pay was lower than expected given the organization’s performance, and those data points above the shaded area suggest the opposite.

1-Year CEO Compensation Realized Percentile vs. Total Shareholder Return Percentile (2016)



                   
   

In the graph above, compensation realized by CVS Health’s CEO in 2016 ranked at the 11th percentile, our TSR ranked at the 17th percentile, indicating that our CEO’s realized compensation was within the range that characterizes an ideal pay-for-performance alignment.

3-Year CEO Compensation Realized Percentile vs. Total Shareholder Return Percentile (2014-16)



                   
   

The graph above illustrates the relationship between CEO pay rank and the relative return to stockholders for CVS Health and the 2017 Peer Group over the 3-year period 2014 to 2016. Relative compensation rests outside of the range that characterizes ideal pay-for-performance alignment. Strong company performance and our disciplined approach to capital allocation over the performance years included in the 2014-2016 measurement period resulted in above target payouts under our LTIP while TSR was impacted in 2016 by a decline in our stock price that was the result of industry-wide pressures on reimbursement, drug pricing and headwinds created by restricted networks adopted by payors in 2016.

5-Year CEO Compensation Realized Percentile vs. Total Shareholder Return Percentile (2012-16)



                   
   

The graph above illustrates the relationship between CEO pay rank and the relative return to shareholders for CVS Health and the 2017 peer group over the five-year period 2012 to 2016. Relative compensation rests within the range that characterizes ideal pay-for-performance alignment.

48 2018 Proxy Statement


Table of Contents

Report of the Compensation Committee: Detailed Program Discussion

                     
             
      The Committee believes this historical view validates that our executive compensation programs work as intended and link pay and performance. The Committee reviews this analysis annually after current data becomes available.      

These assessments demonstrate the Committee’s commitment to maintaining practices that ensure our executive compensation aligns with results in a manner that benefits our investors.

Pay Positioning

CVS Health positions its aggregate target total direct compensation (base salary plus annual and long-term incentives) for its executive officers at competitive pay levels using the median of our peer group for reference. Positioning varies by job and the Committee considers a number of factors including market competitiveness and specific duties and responsibilities of the executive versus those of peers and succession planning. The Committee believes it is appropriate to reward the executive management team with compensation above the competitive median if the ambitious financial targets associated with its variable pay programs are exceeded in a way that is consistent with the Company’s core values.

2017 Peer Group

The Committee assesses financial performance and compensation competitiveness against a group of peer companies that it selects based on input from its independent consultant. The 2017 peer group consisted of the following companies from across general industry that are similar to CVS Health in terms of industry affiliation, labor market, and operating and character image. The Committee reviews the peer group annually and periodically makes changes. No changes were made to the peer group for 2017.

               
   
CVS Health 2017 Compensation Peer Group      

CVS Health vs. Peer Group

AmerisourceBergen Corporation
The Boeing Company
Comcast Corporation
Costco Wholesale Corporation
Express Scripts Holding Company
The Home Depot, Inc.
Johnson & Johnson
The Kroger Co.
McKesson Corporation
Merck & Co., Inc.
PepsiCo, Inc.
Pfizer Inc.
The Procter & Gamble Company
Target Corporation
UnitedHealth Group Incorporated
Walgreens Boots Alliance, Inc.
Wal-Mart Stores, Inc.
The Walt Disney Company

*  Revenue reported for four most recent quarters as of February 28, 2018
**Market capitalization as of December 31, 2017

cvshealthannualmeeting.com 49


Table of Contents

Report of the Compensation Committee: Detailed Program Discussion

Other Compensation Arrangements and Benefits

The Company maintains medical and dental benefits, life insurance and short- and long-term disability insurance programs for all of its employees. Executive officers are eligible to participate in these programs on the same basis and with the same level of financial subsidy as our other salaried employees.

Executive officers may participate in the CVS Future Fund, which is our qualified defined contribution, or 401(k), plan. An eligible CVS Health employee may defer up to 85% of his or her total eligible compensation, defined as salary plus annual incentive, to a maximum defined by the IRS; in 2017, that maximum was $18,000 plus an additional $6,000 for those age 50 and above. After the first full year of employment, CVS Health will match the employee’s deferral dollar-for-dollar up to a maximum equaling 5% of total eligible compensation. CVS Health’s matching cash contributions into the CVS Health Future Fund for the named executive officers who participated are a component of the All Other Compensation Table on page 55.

We offer other benefits that are available to eligible employees, including executive officers, as follows.

Deferred Compensation Plan and Deferred Stock Plan

Eligible executive officers may choose to defer earned and vested compensation into the Deferred Compensation Plan (DCP) and the Deferred Stock Compensation Plan (DSP), which are available to any U.S. employees meeting the Plans’ eligibility criteria. The plans are intended to provide retirement savings in a tax-efficient manner and to enhance stock ownership. The DCP offers a variety of investment crediting choices, none of which represents an above-market return. The individual contributions of each of the named executive officers during fiscal 2017 to the DCP and the DSP, including earnings on those contributions, any distributions during 2017 and total account balances as of the end of 2017, are shown in the Nonqualified Deferred Compensation Table on page 60.

Perquisites and Other Personal Benefits

We provide the following personal benefits to our named executive officers:

Financial planning: An allowance to cover the cost of a Company-provided financial planner to assist with personal financial and estate planning. We believe it is important to provide to our executives the professional expertise required to ensure that they maximize the efficiencies of our compensation and benefit programs and are able to devote their full attention to the management of the Company.
 

Limited personal use of corporate aircraft: We maintain corporate aircraft that may be used by our employees to conduct Company business. Pursuant to an executive security program established by the Board upon the Committee’s recommendation, the CEO is required to use our aircraft for all travel needs, including personal travel, in order to minimize and more efficiently use his travel time, protect the confidentiality of his travel and our business, and enhance his personal security. Certain other named executive officers were also permitted to use our corporate aircraft for personal travel on a very limited basis during fiscal 2017. The amounts are included in “All Other Compensation” and described in the notes following the Summary Compensation Table.
 

Home security: An allowance to the named executive officers to cover the costs of the installation and maintenance of home security monitoring systems. While the Committee believes these security costs are business expenses, disclosure of these costs as personal benefits is required.

The value of all of these items is treated as income taxable to the executives. The aggregate incremental cost to the Company of providing these personal benefits to each of the named executive officers during fiscal 2017 is shown in the Summary Compensation Table on page 54.

Agreements with Executive Officers
As previously disclosed, we have an employment agreement (Employment Agreement) with Mr. Merlo and change in control agreements (CIC Agreements, and together with the Employment Agreement, the Agreements) with Messrs. Denton, Roberts and Moriarty. Ms. Foulkes left the Company in February 2018.

The Committee believes that the interests of stockholders are best served by ensuring that the interests of our senior management are aligned with our stockholders. The change-in-control provisions of the Agreements are intended to eliminate, or at least reduce, the reluctance of senior management to pursue potential change-in-control transactions that may be in stockholders’ best interests. The Agreements serve to eliminate distraction caused by uncertainty about personal financial circumstances during a period in which CVS Health requires focused and thoughtful leadership to ensure a successful outcome. Accordingly, the Agreements provide certain specified “double trigger” severance benefits to the covered executives in the event of their termination under certain circumstances following a change in control. The Committee believes a “double trigger” severance benefit provision is more appropriate, as it provides an incentive for greater continuity in management following a change in control. “Double trigger” benefits require that two events occur in order for severance to be paid, typically a change in control followed by the executive’s involuntary termination of employment. The 2010 and 2017 Incentive Compensation Plans that govern the terms of outstanding equity awards require a “double trigger” for vesting of equity change in control benefits.

50 2018 Proxy Statement


Table of Contents

Report of the Compensation Committee: Detailed Program Discussion

The Committee reviews the severance benefits annually with the assistance of its compensation consultant to evaluate both their effectiveness and competitiveness. The review for fiscal 2017 found the current level of benefits to be within competitive norms for design. Details of payments made to the executives upon a change in control and various termination scenarios; provisions for the treatment of equity awards, SERP and other benefits; and estimated payments that would be made to the executives whose employment terminates following a change in control may be found in Payments/(Forfeitures) Under Termination Scenarios beginning on page 60.

Supplemental Executive Retirement Plan
We maintain an unfunded supplemental retirement plan (SERP), which is designed to supplement the retirement benefits of selected executive officers. The SERP is a legacy plan in which participation has decreased over the years as individuals have retired, and we have not provided SERP benefits to new participants since 2010. Mr. Merlo is the only active executive officer in the SERP. Mr. Merlo has reached the maximum amount of service under the SERP based on his more than 30 years with the Company. As a result, any increase to his benefits would be primarily as a result of performance-based bonuses. See the Pension Benefits Table on page 59 for more information.

Key Policies Related to Compensation

Recoupment

Effective with performance cycles beginning in 2009, we have maintained a recoupment policy that applies to all annual and long-term incentive awards granted to executive officers. The policy applies in cases where financial or operational results used to determine an award amount are meaningfully altered based on fraud or material financial misconduct (collectively, Misconduct), as determined by the Board, and applies to any executive officer determined to have been involved in the Misconduct.

The policy applies to Misconduct committed during the performance period that is discovered during the performance period or the three-year period following the performance period. The policy allows us to recoup the entire award, not only excess amounts generated by the Misconduct, subject to the determination of the Board, and the policy may apply even where there is no financial restatement.

CVS Health’s Anti-Gross-Up Policy

CVS Health maintains a broad policy against tax gross-ups. The only current exception to our anti-gross-up policy is for tax payments that may be due under our broad-based relocation policy, which is applicable to a large number of employees (i.e., those who must relocate upon hire, transfer or promotion).

Insider Trading Policy, Including Anti-Pledging and Hedging

A significant percentage of executive compensation has been payable in CVS Health common stock. The Board and executive management of CVS Health take seriously their responsibilities and obligations to exhibit the highest standards of behavior relative to selling and trading our stock. All transactions in our stock contemplated by any director, executive officer or designated employee who has a significant role in, or access to, our financial reporting process (collectively, lnsiders), must be pre-cleared by either the General Counsel or the Corporate Secretary. Insiders are generally prohibited from trading in any of our securities except during periods of varying length beginning shortly after the release of our financial results for each quarter, and Insiders and other employees may be required to refrain from trading during other designated periods when significant developments or announcements are anticipated. In addition, it is our policy that Insiders and other employees may not engage in any of the following activities with respect to our securities:

Trading in our securities on a short-term basis (stock purchased in the open market must be held for at least six months);
 

Purchasing stock on margin or pledging our stock or any stock incentive award as collateral for a loan or margin account;
 

Engaging in short sales or purchases of our stock;
 

Buying or selling puts, calls, exchange traded options or other derivative securities; or
 

Engaging in any other hedging transactions, which includes transactions designed to offset any decrease in the market value of equity securities.

Our most senior executives and Board members are generally required to transact in our stock pursuant to a 10b5-1 trading plan, and our other executives are encouraged to use trading plans. A trading plan is a contract that allows the individual to sell a pre-determined number of shares at a time in the future when pre-determined conditions in the plan are met. However, there are extensive guidelines that govern the use of 10b5-1 trading plans including the timing of entry or modification of a plan, the price at which shares will be traded, a “cooling off” period during which no trades can take place, minimum and maximum terms, restrictions on the number of plans an individual can maintain, a prohibition on trading outside of the plan, and pre-approval of plans (and any modification of plans) by the General Counsel or Corporate Secretary.

cvshealthannualmeeting.com 51


Table of Contents

Report of the Compensation Committee: Detailed Program Discussion

Compliance with Section 162(m) of the Internal Revenue Code

Section 162(m) of the Internal Revenue Code (IRC 162(m)), as amended by the recently enacted Tax Cuts and Jobs Act of 2017 (the 2017 Act), generally disallows a deduction for federal tax purposes to any publicly traded corporation for any remuneration in excess of $1 million paid in any taxable year to its chief executive officer, chief financial officer and the three other most highly compensated executive officers at year end. Prior to the amendment, qualifying “performance-based compensation” was not subject to the deduction limitation if specified requirements were met. Under the 2017 Act, the performance-based exception has been repealed with respect to federal income taxes. The new rules generally apply to taxable years beginning after December 31, 2017, but do not apply to compensation provided pursuant to a written binding contract in effect on November 2, 2017 that is not modified in any material respect after that date.

The Committee has historically designed certain portions of our named executive officers’ compensation in order to qualify such compensation as performance-based compensation under IRC 162(m). While the Committee considers the deductibility of executive compensation under IRC 162(m), the Committee believes it is important to retain flexibility to structure the Company’s executive compensation program and practices in a manner that the Committee determines is in the best interests of CVS Health and its stockholders. The Committee retains discretion to operate the Company’s executive compensation programs in a manner designed to promote varying company goals. As a result, the Committee may from time to time conclude that certain compensation arrangements are in the best interests of CVS Health and its stockholders and consistent with its compensation philosophy and strategy, despite the fact that the arrangements might not qualify for tax deductibility. The Committee is continuing to assess the impact of IRC 162(m), as amended, on the Company’s executive compensation programs and practices.

Non-GAAP Financial Measures Used in Compensation Discussion and Analysis

Throughout this Compensation Discussion and Analysis, we refer to various financial measures. The majority of these financial measures are calculated in accordance with U.S. generally accepted accounting principles, or GAAP. However, there are some financial measures that management adjusts in order to assess our year-over-year performance. These adjusted financial measures are commonly referred to as non-GAAP. An explanation of how we calculate these non-GAAP financial measures is included below.

               
     
Adjusted Income from Continuing Operations

Adjusted Income from Continuing Operations Attributable to CVS Health is defined as follows:

Income before income tax provision
 
Plus (minus): Non-GAAP adjustments not part of the underlying business performance
 
Less: Adjusted income tax provision (using the adjusted effective tax rate, adjusted for the items above)
 
Plus (minus): Net loss (income) attributable to noncontrolling interest
 
Less: Earnings allocated to participating securities

Adjusted Operating Profit (MIP) or MIP Adjusted Operating Profit

Adjusted Operating Profit (MIP) or MIP Adjusted Operating Profit is defined as earnings before interest and taxes adjusted for certain items. For the purposes of measuring performance against established targets in any period, when applicable those excluded items comprise certain legal settlements, store rationalization impairment charges, settlements of pension obligations, goodwill impairments, the impact of hurricanes, severance-related costs, and activity related to newly acquired or divested businesses.

Free Cash Flow

We define Free Cash Flow as net cash provided by operating activities less net additions to property and equipment (i.e., additions to property and equipment plus proceeds from sale-leaseback transactions).

RoNA or Return on Net Assets

RoNA, or Return on Net Assets, is calculated by dividing adjusted net operating profit after tax (Adjusted NOPAT) by the most recent two year’s Adjusted Average Net Assets. Adjusted NOPAT is Operating Profit adjusted for certain financial items described below. Adjusted Average Net Assets for the purposes of this calculation is defined as current assets plus net fixed assets less accounts payable and accrued expenses adjusted for certain financial items described below. For the purposes of measuring performance against established targets in any period, Adjusted NOPAT and Adjusted Average Net Assets exclude from operating profit and average net assets, respectively, after tax amounts related to newly acquired or divested businesses, adjustments to legal reserves in connection with certain legal settlements, store rationalization impairment charges, settlements of pension obligations, goodwill impairments, the impact of hurricanes, and severance-related costs. The impact of tax reform is also reversed. Adjusted Average Net Assets also excludes cash associated with the pre-funding for the 2017 accelerated share repurchase agreement, as well as the financial impact of the change in accounting principle associated with the classification of deferred tax assets.

52 2018 Proxy Statement


Table of Contents

Report of the Compensation Committee: Detailed Program Discussion

Relative TSR Peer Group for 2018 LTIP

               
     
S&P 500 Health Care
     
Abbott Laboratories    CVS Health Corporation    Medtronic plc
AbbVie Inc. Danaher Corporation Merck & Co., Inc.
Aetna Inc. DaVita Inc. Mettler-Toledo International Inc.
Agilent Technologies, Inc. Dentsply Sirona Inc. Mylan N.V.
Alexion Pharmaceuticals, Inc. Edwards Lifesciences Corporation Patterson Companies, Inc.
Align Technology, Inc. Eli Lilly and Company PerkinElmer, Inc.
Allergan plc Envision Healthcare Corporation Perrigo Company plc
AmerisourceBergen Corporation Express Scripts Holding Company Pfizer Inc.
Amgen Inc. Gilead Sciences, Inc. Quest Diagnostics Incorporated
Anthem, Inc. HCA Healthcare, Inc. Regeneron Pharmaceuticals, Inc.
Baxter International Inc. Henry Schein, Inc. Stryker Corporation
Becton, Dickinson and Company Hologic, Inc. The Cooper Companies, Inc.
Biogen Inc. Humana Inc. Thermo Fisher Scientific Inc.
Boston Scientific Corporation IDEXX Laboratories, Inc. UnitedHealth Group Incorporated
Bristol-Myers Squibb Company Illumina, Inc. Universal Health Services, Inc.
Cardinal Health, Inc. Incyte Corporation Varian Medical Systems, Inc.
Celgene Corporation Intuitive Surgical, Inc. Vertex Pharmaceuticals Incorporated
Centene Corporation Johnson & Johnson Waters Corporation
Cerner Corporation Laboratory Corporation of America Holdings Zimmer Biomet Holdings, Inc.
Cigna Corporation Mallinckrodt Public Limited Company Zoetis Inc.
McKesson Corporation
     
S&P 500 Consumer Staples
     
Altria Group, Inc.    General Mills, Inc.    The Clorox Company
Archer-Daniels-Midland Company Hormel Foods Corporation The Coca-Cola Company
Brown-Forman Corporation Kellogg Company The Estée Lauder Companies Inc.
Campbell Soup Company Kimberly-Clark Corporation The Hershey Company
Church & Dwight Co., Inc. McCormick & Company, Incorporated The J. M. Smucker Company
Colgate-Palmolive Company Molson Coors Brewing Company The Kraft Heinz Company
Conagra Brands, Inc. Mondelez International, Inc. The Kroger Co.
Constellation Brands, Inc. Monster Beverage Corporation The Procter & Gamble Company
Costco Wholesale Corporation Pepsico, Inc. Tyson Foods, Inc.
Coty Inc. Philip Morris International Inc. Wal-Mart Stores, Inc.
CVS Health Corporation Reynolds American Inc. Walgreens Boots Alliance, Inc.
Dr. Pepper Snapple Group, Inc. Sysco Corporation Whole Foods Market, Inc.

cvshealthannualmeeting.com 53


Table of Contents

   

Executive Compensation Tables

Summary Compensation Table

The following Summary Compensation Table shows information about the compensation received by our CEO, CFO and each of our three other most highly compensated executive officers for services rendered in all capacities during the 2017 fiscal year.

Summary Compensation Table

Name & Principal 2017
Positions 1
    Year        Salary
($)
       Bonus
($)
      Stock
Awards
($) 2 3 4
      Option
Awards
($) 2 3
       Non-Equity
Incentive Plan
Compensation
($) 5
       Change In
Pension
Value and
Nonqualified
Deferred
Compensation
Earnings
($) 6
       All
Other
Compensation
($) 7
       Total
($)
Larry J. Merlo
President and Chief
Executive Officer
2017 1,630,000 3,374,960 3,374,998 3,118,800 754,106 12,252,864
2016 1,630,000 3,999,931 3,999,990 7,882,000 847,456 18,359,377
2015 1,560,000 6,749,900 3,999,993 9,692,596 6,087,680 852,885 28,943,054
David M. Denton
Executive Vice
President and Chief
Financial Officer
2017 850,000 999,977 999,997 1,193,000 334,979 4,377,953
2016 850,000 999,983 999,987 2,380,000 319,026 5,548,996
2015 843,750 1,874,937 874,999 3,077,597 289,298 6,960,581
Helena B. Foulkes
Executive
Vice President
and President –
CVS Pharmacy
2017 950,000 1,499,965 1,499,990 169,006 4,118,961
2016 950,000 999,983 999,987 2,002,000 210,213 5,162,183
2015 925,000 1,749,937 874,999 2,283,078 232,314 6,065,328
    
Jonathan C. Roberts
Executive
Vice President
and Chief –
Operating Officer
2017 1,033,333 1,999,953 1,999,994 1,605,000 244,484 6,882,764
2016 950,000 2,249,961 2,249,999 2,907,000 274,147 8,631,107
2015 937,500 2,124,898 999,995 3,397,597 280,559 7,740,549
 
Thomas M. Moriarty
Executive
Vice President,
Chief Policy and
External Affairs Officer
and General Counsel
2017 750,000 1,249,971 1,249,998 1,160,000 102,585 4,512,554
2016 750,000 999,983 999,987 2,026,000 174,770 4,950,740
2015 730,000 1,624,975 749,989 2,656,298 163,131 5,924,393
 
1

On March 2, 2017, the Company announced that Mr. Roberts was appointed Executive Vice President and Chief Operating Officer and Mr. Moriarty was appointed Executive Vice President, Chief Policy and External Affairs Officer and General Counsel. Ms. Foulkes resigned from the Company effective February 9, 2018. For purposes of 2017 disclosure, this proxy statement reflects each executive’s title as of December 31, 2017.

2

The figures shown are the full grant date fair value of time-based RSU awards and option awards made to each executive in 2017.

3

For a discussion of the assumptions and methodologies used to value the stock and option awards, please see the discussion of stock awards and option awards contained in our 2017 Annual Report to Stockholders, Notes to Consolidated Financial Statements at Note 10, “Stock Incentive Plans”.

4

The amount reported for 2015 includes 50% of the value of the LTIP award granted to each executive in that year, representing the portion of the LTIP to be settled in stock at target performance. As discussed on page 35, in response to stockholder feedback, beginning with the 2016-2018 performance cycle LTIP awards are now denominated in cash and settled 100% in stock (rather than cash and stock). As a result and consistent with SEC reporting rules, the full amount of the LTIP award to be paid in 2016 and 2017 will be reported in the Summary Compensation Table in the Non-Equity Incentive Plan column for the year it vests, not the year of grant.

If these changes had not been made to the LTIP design, the following additional amounts would have been reported in both 2016 and 2017: Mr. Merlo $3,375,000; Mr. Denton $1,000,000; Ms. Foulkes $1,000,000; and Mr. Moriarty $937,500. For Mr. Roberts, the additional amount would have been $1,500,000 in 2016 and $1,875,000 in 2017.

5

The figures shown include amounts earned in 2017 as annual cash incentive awards (see page 44) and the cash portion of the 2015 LTIP award (see page 46). Beginning with the 2016-2018 performance cycle, LTIP awards will now be settled in stock and reported in the final year of the cycle. Awards will be reported in the Non-Equity Incentive Plan column because they are denominated in cash and then paid in common stock that is subject to a two-year holding requirement.

6

The amounts reported in this column represent only changes in pension value, as the Company does not pay above-market earnings on deferred compensation. The value of Mr. Merlo’s pension benefit decreased by $751,844 in 2017 from the prior year’s valuation; however, under SEC rules the negative change in the pension value is disclosed as $0. The Company adopted a policy in 2010 stating that it will not offer SERP benefits to new participants. Mr. Merlo is the only executive participant in the SERP. For additional information on the SERP, see “Pension Benefits” beginning on page 58.

7

Set forth below is additional information regarding the amounts disclosed in the All Other Compensation column for 2017.


54 2018 Proxy Statement


Table of Contents

Executive Compensation Tables: Summary Compensation Table

All Other Compensation – 2017


Name & Principal 2017 Positions Perquisites &
Other Personal
Benefits
A
($)
Company
Contributions
to Defined
Contribution
Plans B
($)
Other C
($)
Larry J. Merlo        68,146        200,600        485,360
President and Chief Executive Officer
David M. Denton 21,391 24,000 289,588
Executive Vice President and Chief Financial Officer
Helena B. Foulkes 15,360 85,100 68,546
Executive Vice President and President – CVS Pharmacy
Jonathan C. Roberts 25,204 109,517 109,763
Executive Vice President and Chief Operating Officer
Thomas M. Moriarty 20,755 24,000 57,830
Executive Vice President, Chief Policy and External Affairs Officer and General Counsel
A

The amounts above reflect the following: for Mr. Merlo, $15,000 for financial planning services, $180 for home security, $44,966 associated with personal use of company aircraft and $8,000 associated with the CVS Health Charity Classic; for Mr. Denton, $15,000 for financial planning services, $465 for home security and $5,926 associated with personal use of company aircraft; for Ms. Foulkes, $15,000 for financial planning services and $360 for home security; for Mr. Roberts, $15,000 for financial planning services, $1,932 for home security, $272 associated with personal use of company aircraft and $8,000 associated with the CVS Health Charity Classic; for Mr. Moriarty, $15,000 for financial planning services, $755 associated with personal use of company aircraft and $5,000 associated with the CVS Health Charity Classic. The Company determines the amount associated with personal use of Company aircraft by calculating the incremental cost to the Company based on the cost of fuel, trip-related maintenance, deadhead flights, crew travel expenses, landing fees, trip-related hangar costs and smaller variable expenses.

B

For 2017, this amount includes Company matching contributions to the CVS Health Future Fund of $13,500 for each of Messrs. Merlo, Denton, Roberts and Moriarty and Ms. Foulkes. It also includes Company matching contributions credited to notional accounts in the unfunded Deferred Compensation Plan equal to: for Mr. Merlo $187,100; for Mr. Denton, $10,500; for Ms. Foulkes, $71,600; for Mr. Roberts, $96,017; and for Mr. Moriarty, $10,500.

C

This amount includes cash dividend equivalents paid by the Company on unvested RSUs as follows: for Mr. Merlo, $316,012; for Mr. Denton, $289,588; for Ms. Foulkes, $68,546; for Mr. Roberts, $98,111; and for Mr. Moriarty, $57,830. Also includes cash dividends paid by the Company on deferred RSUs, as noted in the Nonqualified Deferred Compensation table: for Mr. Merlo, $169,348 and Mr. Roberts, $11,652.


cvshealthannualmeeting.com 55


Table of Contents

Executive Compensation Tables: Grants of Plan-Based Awards

Grants of Plan-Based Awards

This table reflects awards granted under our annual cash incentive plan for 2017, the 2017 – 2019 LTIP cycle, and the annual equity awards for 2017, which include stock options and RSUs.

Grants of Plan-Based Awards – 2017


Date of
Committee
Action
Est. Future Payouts
Under Non-Equity
Incentive Plan Awards 1





Est. Future Payouts
Under Equity
Incentive Plan Awards
All
Other
Stock
Awards:
Number
of Shares
of Stock
or Units
(#)
All
Other
Option
Awards:
Number of
Securities
Underlying
Options
(#)
Exercise
or Base
Price of
Option
Awards
($ / Sh)
Grant
Date Fair
Value of
Stock
and
Option
Awards
($)
Name & Principal
2017 Positions
Award Type Grant
Date
Threshold
($) 2
Target
($)
Maximum
($)
Threshold
(#) 2
Target
(#)
Maximum
(#)
Larry J. Merlo
President and Chief Executive Officer
Stock Options 2/15/2017 4/3/2017 338,105 78.05    3,374,998
   Annual RSUs    2/15/2017    4/3/2017                      43,241          3,374,960
Annual Cash 1,630,000 3,260,000 6,520,000
LTIP (17-19) 1 2/15/2017 2,700,000 6,750,000   13,500,000
David M. Denton
Executive Vice President and Chief Financial Officer
Stock Options 2/15/2017 4/3/2017 100,179 78.05 999,997
Annual RSUs 2/15/2017 4/3/2017 12,812 999,977
Annual Cash 637,500 1,275,000 2,550,000
LTIP (17-19) 1 2/15/2017 800,000 2,000,000 4,000,000
Helena B. Foulkes
Executive Vice President and President – CVS Pharmacy
Stock Options 2/15/2017 4/3/2017 150,268 78.05   1,499,990
Annual RSUs 2/15/2017 4/3/2017 19,218 1,499,965
Annual Cash 712,500 1,425,000 2,850,000
LTIP (17-19) 1 2/15/2017 800,000 2,000,000 4,000,000
Jonathan C. Roberts
Executive Vice President and Chief Operating Officer
Stock Options 2/15/2017 4/3/2017 200,358 78.05   1,999,994
Annual RSUs 2/15/2017 4/3/2017 25,624 1,999,953
Annual Cash 918,750 1,837,500 3,675,000
LTIP (17-19) 1 2/15/2017 1,500,000 3,750,000 7,500,000
Thomas M. Moriarty
Executive Vice President, Chief Policy and External Affairs Officer and General Counsel
Stock Options 2/15/2017 4/3/2017 125,224 78.05   1,249,998
Annual RSUs 2/15/2017 4/3/2017 16,015 1,249,971
Annual Cash 562,500 1,125,000 2,250,000
LTIP (17-19) 1 2/15/2017 750,000 1,875,000 3,750,000
1

Represents the value, denominated in cash, at grant. Beginning with the 2016-2018 LTIP cycle, awards will be settled 100% in CVS Health common stock adjusted for performance. At the end of the three year cycle, final awards will be disclosed in the Summary Compensation Table under the column “Non-Equity Incentive Plan Compensation”. Prior to the 2016-2018 LTIP cycle, awards were settled in equal portions of stock and cash and reported in the Option Exercises and Stock Vested Table and the Summary Compensation Table, respectively.

2

Represents the threshold achievement in order to receive a payout under the respective plan; performance below threshold results in no payout.

The stock option awards shown above vest in equal installments on the first, second, third and fourth anniversaries of the date of grant and expire seven years from the date of grant. As described above, our policy is to establish the exercise price for stock options as the closing sale price of our common stock on the grant date. Annual RSU grants typically vest in increments of 50% on the third anniversary of the date of grant and 50% on the fifth anniversary of the date of grant.

56 2018 Proxy Statement


Table of Contents

Executive Compensation Tables: Outstanding Equity Awards at Fiscal Year-End

Outstanding Equity Awards at Fiscal Year-End

This table reflects stock option and RSU awards granted to our named executive officers under our ICPs that were outstanding as of December 31, 2017.

Outstanding Equity Awards at 2017 Year-End


Stock Option Awards Stock Awards
Name & Principal
2017 Positions
     Grant
Date
     Number of
Securities
Underlying
Unexercised
Options (#)
Exercisable
     Number of
Securities
Underlying
Unexercised
Options (#)
Unexercisable
     Option
Exercise
Price
($)
     Option
Expiration
Date
     Grant
Date
     Number of
Shares or
Units of Stock
That Have
Not Vested
(#)
     Market Value
of Shares or
Units of Stock
That Have
Not Vested
($) 1
Larry J. Merlo
President and Chief Executive Officer
4/2/2012 332,736 2 45.07 4/2/2019 4/1/2013 36,678 4 2,659,155
4/1/2013 314,713 2 54.53 4/1/2020 4/1/2014 26,922 4 1,951,845
4/1/2014 251,772 83,925 2 74.29 4/1/2021 4/1/2015 39,115 4 2,835,838
4/1/2015 136,964 136,965 2 102.26 4/1/2022 4/1/2016 38,160 4 2,766,600
4/1/2016 71,696 215,091 2 104.82 4/1/2023 4/3/2017 43,241 4 3,134,973
4/3/2017 338,105 2 78.05 4/3/2024
David M. Denton
Executive Vice President and Chief Financial Officer
4/1/2014 47,207 15,736 2 74.29 4/1/2021 4/1/2010 4,313 5 312,693
4/1/2015 29,960 29,962 2 102.26 4/1/2022 4/1/2013 12,608 4 914,080
4/1/2016 17,924 53,772 2 104.82 4/1/2023 4/1/2014 5,048 4 365,980
4/3/2017 100,179 2 78.05 4/3/2024 4/1/2014 100,000 6 7,250,000
4/1/2015 8,556 4 620,310
4/1/2016 9,540 4 691,650
4/3/2017 12,812 4 928,870
Helena B. Foulkes
Executive Vice President and President – CVS Pharmacy
4/2/2012 19,965 2 45.07 4/2/2019 4/1/2009 2,670 5 193,575
4/1/2014 39,339 13,113 2 74.29 4/1/2021 4/1/2010 2,416 5 175,160
4/1/2015 29,960 29,962 2 102.26 4/1/2022 4/2/2013 4,585 4 332,413
4/1/2016 17,924 53,772 2 104.82 4/1/2023 4/1/2014 4,206 4 304,935
4/3/2017 150,268 2 78.05 4/3/2024 4/1/2015 8,556 4 620,310
4/1/2016 9,540 4 691,650
4/3/2017 19,218 4 1,393,305
Jonathan C. Roberts
Executive Vice President and Chief Operating Officer
4/2/2012 77,639 2 45.07 4/2/2019 4/1/2013 8,024 4 581,740
9/4/2012 108,870 3 45.93 9/4/2022 4/1/2014 5,889 4 426,953
4/1/2013 68,844 2 54.53 4/1/2020 4/1/2015 9,778 4 708,905
4/1/2014 55,074 18,359 2 74.29 4/1/2021 4/1/2016 21,465 4 1,556,213
4/1/2015 34,241 34,241 2 102.26 4/1/2022 4/3/2017 25,624 4 1,857,740
4/1/2016 40,329 120,989 2 104.82 4/1/2023
4/3/2017 200,358 2 78.05 4/3/2024
Thomas M. Moriarty
Executive Vice President, Chief Policy and Ext. Affairs Officer and General Counsel
4/1/2014 47,207 15,736 2 74.29 4/1/2021 4/1/2013 5,731 4 415,498
4/1/2015 25,680 25,681